**Exhibit      10.5**

**UBC      SUBLICENCE AGREEMENT**

**BY      AND BETWEEN**

**HANA      PHARMACEUTICALS CORPORATION**

**AND**

**INEX      PHARMACEUTICALS CORPORATION**

----

**SUBLICENCE      AGREEMENT**

**Table      of Contents**

| Article                1 DEFINITIONS                              | 1                                                                       |
|-------------------------------------------------------------------|-------------------------------------------------------------------------|
| 1.1                                                               | Definitions                                                             | 1 |
| 1.2                                                               | Other                Definitions                                        | 13 |
|                                                              |                                                                    |   |
| Article                2 PROPERTY RIGHTS IN AND TO THE TECHNOLOGY | 13                                                                      |
| 2.1                                                               | University’s                Intellectual Property Rights          | 13 |
|                                                              |                                                                    |   |
| Article                3 GRANT OF SUBLICENCE TO HANA              | 14                                                                      |
| 3.1                                                               | Sublicense                Grant To Hana                                 | 14 |
| 3.2                                                               | License                Grant to INEX                                    | 14 |
| 3.3                                                               | Compliance                with UBC License                              | 14 |
| 3.4                                                               | Payment                of Taxes                                         | 14 |
|                                                              |                                                                    |   |
| Article                4 SUBLICENSING BY HANA                     | 15                                                                      |
| 4.1                                                               | UBC                Consent                                              | 15 |
| 4.2                                                               | Sublicenses                to Affiliates                                | 15 |
| 4.3                                                               | Furnish                Sublicense Post Execution                        | 15 |
| 4.4                                                               | Covenants                by Hana’s Sublicensee                    | 15 |
| 4.5                                                               | Covenants                by Hana                                        | 16 |
| 4.6                                                               | Covenants                by Hana’s Sublicensee                    | 17 |
| 4.7                                                               | Confirmation                from the University                         | 17 |
|                                                              |                                                                    |   |
| Article                5 ROYALTIES AND CONSIDERATION              | 17                                                                      |
| 5.1                                                               | Assumption                of Royalty Obligations                        | 17 |
| 5.2                                                               | Royalty                Due UBC                                          | 18 |
| 5.3                                                               | Rates                Established by UBC License                         | 18 |
| 5.4                                                               | One                Royalty Per Product Payable to UBC                   | 18 |
| 5.5                                                               | Payment                of Royalty Due UBC                               | 19 |
| 5.6                                                               | Interest                Due to University                               | 20 |
| 5.7                                                               | Sublicensing                and Royalty Payments to INEX                | 21 |
|                                                              |                                                                    |   |
| Article                6 PATENTS                                  | 31                                                                      |
| 6.1                                                               | IP                Committee                                             | 31 |
| 6.2                                                               | Responsibility                for Patent Prosecution and Maintenance    | 31 |
| 6.3                                                               | Identification                of Additional Process or Use              | 32 |
| 6.4                                                               | Issuance                of Patent                                       | 33 |
| 6.5                                                               | Improvements                                                            | 33 |
| 6.6                                                               | Consultation                and Reporting                               | 33 |
| 6.7                                                               | Reports                                                                 | 34 |
| 6.8                                                               | Abandonment,                Withdrawal or Discontinuance                | 34 |
| 6.9                                                               | Costs                of Patent Application, Prosecution and Maintenance | 36 |
| 6.10                                                              | Late                Payments                                            | 37 |
| 6.11                                                              | Co-operation                                                            | 37 |
| 6.12                                                              | Injunctive                Relief                                        | 37 |
|                                                              |                                                                    |   |

----

| Article                7 DISCLAIMERS, REPRESENTATIONS AND WARRANTIES | 37                                                            |
|----------------------------------------------------------------------|---------------------------------------------------------------|
| 7.1                                                                  | Disclaimer                                                    | 37 |
| 7.2                                                                  | International                Sale of Goods Act Not Applicable | 38 |
| 7.3                                                                  | No                Implied Warranties                          | 38 |
| 7.4                                                                  | Limited                Warranty                               | 38 |
| 7.5                                                                  | Conduct                of Infringement Proceedings            | 38 |
| 7.6                                                                  | Breach                of Confidence Proceedings               | 40 |
| 7.7                                                                  | Defense                of Infringement Proceedings            | 40 |
| 7.8                                                                  | Co-operation                with Other Licensees              | 42 |
| 7.9                                                                  | Hana                Representations and Warranties            | 42 |
| 7.10                                                                 | INEX                Representations and Warranties            | 43 |
|                                                                 |                                                          |   |
| Article                8 INDEMNITY AND LIMITATION OF LIABILITY       | 44                                                            |
| 8.1                                                                  | Rights                of the University                       | 44 |
| 8.2                                                                  | Indemnification                by INEX                        | 45 |
| 8.3                                                                  | Indemnification                by Hana                        | 45 |
| 8.4                                                                  | Notice                of Claims                               | 46 |
| 8.5                                                                  | Consequential                Losses                           | 46 |
| 8.6                                                                  | Action                Between the Parties                     | 47 |
|                                                                 |                                                          |   |
| Article                9 PUBLICATION AND CONFIDENTIALITY             | 47                                                            |
| 9.1                                                                  | Treatment                of Confidential Information          | 47 |
| 9.2                                                                  | Publications                                                  | 47 |
| 9.3                                                                  | Objections                to Publication                      | 48 |
| 9.4                                                                  | Permitted                Disclosures                          | 48 |
| 9.5                                                                  | Liability                for Representatives                  | 49 |
| 9.6                                                                  | No                Limitation on Regulatory Compliance         | 49 |
| 9.7                                                                  | Return                of Confidential Information             | 50 |
|                                                                 |                                                          |   |
| Article                10 PRODUCTION AND MARKETING                   | 50                                                            |
| 10.1                                                                 | No                Use of Names and Trademarks                 | 50 |
| 10.2                                                                 | Labeling                and Patent Marking                    | 50 |
| 10.3                                                                 | Development                and Commercialization Efforts      | 50 |
| 10.4                                                                 | Consequence                of No Sales                        | 52 |
| 10.5                                                                 | Reports                on Commercialization                   | 52 |
| 10.6                                                                 | Development                Plans                              | 53 |
| 10.7                                                                 | Reports                on Development                         | 53 |
| 10.8                                                                 | Regulatory                Compliance                          | 53 |
|                                                                 |                                                          |   |
| Article                11 ACCOUNTING RECORDS                         | 54                                                            |
| 11.1                                                                 | Documentation                                                 | 54 |
| 11.2                                                                 | Reporting                                                     | 54 |
| 11.3                                                                 | Method                of Calculation                          | 54 |
| 11.4                                                                 | Record                Retention                               | 54 |
| 11.5                                                                 | Confidential                Treatment                         | 55 |
|                                                                 |                                                          |   |
| Article                12 INSURANCE                                  | 55                                                            |
| 12.1                                                                 | Insurance                                                     | 55 |
|                                                                 |                                                          |   |
| Article                13 ASSIGNMENT                                 | 56                                                            |
| 13.1                                                                 | Assignment                                                    | 56 |
|                                                                 |                                                          |   |

----

| Article                14 GOVERNING LAW AND ARBITRATION                  | 57                                                    |
|--------------------------------------------------------------------------|-------------------------------------------------------|
| 14.1                                                                     | Governing                Law                          | 57 |
| 14.2                                                                     | Jurisdiction                                          | 57 |
| 14.3                                                                     | Arbitration                                           | 57 |
|                                                                     |                                                  |   |
| Article                15 NOTICES                                        | 58                                                    |
| 15.1                                                                     | Notices                                               | 58 |
|                                                                     |                                                  |   |
| Article                16 TERM                                           |                                                  | 59 |
| 16.1                                                                     | Term                                                  | 59 |
|                                                                     |                                                  |   |
| Article                17 TERMINATION                                    | 59                                                    |
| 17.1                                                                     | Termination                for Bankruptcy             | 59 |
| 17.2                                                                     | Termination                by INEX                    | 61 |
| 17.3                                                                     | Termination                for Invalidity Challenge   | 62 |
| 17.4                                                                     | Termination                for Material Breach        | 62 |
| 17.5                                                                     | No                Limitation on Remedies              | 62 |
| 17.6                                                                     | Consequence                of Termination             | 62 |
| 17.7                                                                     | Return                of Confidential Information     | 65 |
|                                                                     |                                                  |   |
| Article                18 MISCELLANEOUS COVENANTS REQUIRED BY UNIVERSITY | 65                                                    |
| 18.1                                                                     | Miscellaneous                Covenants of Hana        | 65 |
|                                                                     |                                                  |   |
| Article                19 PRODUCT SAFETY AND REGULATORY COMPLIANCE       | 66                                                    |
| 19.1                                                                     | Regulatory                Responsibilities            | 66 |
| 19.2                                                                     | Pharmacovigilance                                     | 66 |
| 19.3                                                                     | Recalls                and Product Withdrawals        | 67 |
|                                                                     |                                                  |   |
| Article                20 GENERAL PROVISIONS                             | 67                                                    |
| 20.1                                                                     | UBC                Requirement                        | 67 |
| 20.2                                                                     | Amendments                                            | 67 |
| 20.3                                                                     | Counterparts;                Facsimile                | 68 |
| 20.4                                                                     | Enurement                                             | 68 |
| 20.5                                                                     | Exhibits                / Schedules                   | 68 |
| 20.6                                                                     | Force                Majeure                          | 68 |
| 20.7                                                                     | Further                Assurances                     | 68 |
| 20.8                                                                     | Headings                                              | 68 |
| 20.9                                                                     | Incorporation                by Reference             | 68 |
| 20.10                                                                    | Independent                Legal Advice               | 68 |
| 20.11                                                                    | Non-Use                of Names                       | 69 |
| 20.12                                                                    | No                Implied Rights                      | 69 |
| 20.13                                                                    | No                Solicitation or Hiring of Employees | 69 |
| 20.14                                                                    | No                Waiver                              | 69 |
| 20.15                                                                    | Publicity                                             | 69 |
| 20.16                                                                    | Relationship                of Parties                | 69 |
| 20.17                                                                    | Rights                and Remedies                    | 70 |
| 20.18                                                                    | Severability                                          | 70 |
| 20.19                                                                    | Survival                                              | 71 |
| 20.20                                                                    | Wording                                               | 71 |
| 20.21                                                                    | Supremacy                                             | 71 |

----

**SUBLICENCE      AGREEMENT**

**INEX      PHARMACEUTICALS CORPORATION**

**INEX**

**HANA      BIOSCIENCES, INC.**

**Hana**

| A.   | Pursuant                to a License Agreement between INEX and the University of British                Columbia                (the “**University**”)                dated effective July 1, 1998, the University has exclusively licensed                to                INEX, certain patents and technology invented, developed and/or acquired                by the University relating to liposomal drug delivery                technologies. |
|----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| B.   | Pursuant                to an Asset Purchase Agreement between INEX and Hana dated May 6,                2006                (the “**Asset                Purchase Agreement**”),                INEX wishes to sublicense to Hana, certain of the patents and technology                licensed by the University to INEX relating to ionophore loading                and                sphingosome preparation, including methods and apparatus, for use                solely                within the Hana Field (as hereinafter                defined). |
|----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| C.   | INEX                and Hana desire to set out in this Agreement the terms and conditions                which will govern the Parties’ respective rights and obligations in                respect of the sublicensed patents and technology relating to ionophore                loading and sphingosome preparation, including methods and                apparatus. |
|----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Article      1**
**      DEFINITIONS**

**1.1  **
**Definitions**

| (a)   | “**Abandoning                Party**”                shall have the meaning set forth in Section 6.8. |
|-----------------|-------------------------------------------------------------------------------------------------------------------|

----

| (b)   | “**Accounting**”                means an accounting statement setting out in detail how the amount                of                Revenue Due UBC and Sublicensing Revenue Due UBC received by Hana                and its                Sublicensees is determined. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | “**Affiliate**”                or “**Affiliated                Company**”                or “**Affiliated                Companies**”                means with respect to any specified person, any other person that                directly                controls, is controlled by, or is under common control with, such                specified person. For the purposes of this Section, “**control**”                shall mean: |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | in                the case of corporate entities, the direct or indirect ownership                of at                least 50% of the stock or participating shares entitled to vote in                the                general meeting of shareholders,                and |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | in                the case of a partnership or other legal entity, ownership of at                least 50%                interest in the income or at least a 50% interest in the power to                direct                the management or policies of such                entity. |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (d)   | “**Agreement**”                means this Sublicense Agreement and                all Schedules attached hereto. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------|

| (e)   | “**Annual                Maintenance Fee**”** **shall                have the meaning set forth in Section 5.5(k). |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------|

| (f)   | “**Applicable                Laws**”                means all applicable federal, provincial, state and local laws,                ordinances, rules and regulations of any kind whatsoever in the Territory,                including, without limitation, pharmaceutical and environmental rules                and                regulations, including cGMP Requirements, GCP Requirements, GLP                Requirements and the General Biological Products Standards of the                FDA, and                the Federal Food, Drug and Cosmetic Act, as amended, or any successor                act                thereto (“**FDCA**”). |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (g)   | “**Business                Day**”                means any day other than a day which is a Saturday, a Sunday or a                statutory holiday in British Columbia                or                California. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (h)   | “**Calendar                Quarter**”                means each of the three-month periods ending on March 31,                June 30, September 30 or December                31. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | "**cGMP                Requirements**"                means the current Good Manufacturing Practices standards required                by the                FDA (as set forth in the FDCA), the Therapeutic Products Directorate                Organization of Health Canada ("**TPD**"),                and the European Medicines Evaluation Agency ("**EMEA**")                and any other jurisdiction as mutually agreed between the Parties                together                with their applicable regulations, policies or guidelines which are                in                effect for the manufacture and testing of pharmaceutical materials,                active                ingredients, or excipients for use in Phase I, Phase II, and Phase                III                clinical trials, as applicable. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (j)   | “**Clinical                Activity**”                and “**Clinical                Activities**”                mean any one or more of the activities associated with drug testing                in                humans, including trial design and execution, payment of investigators’,                institutional, and contractors’ fees, drug distribution and                accountability, analytical testing, data management, statistical                analysis,                adverse event reporting, and scientific publication, performed in                pursuit                of the Development and Commercialization of                Product. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (k)   | “**Clinical                Trial Material**”                means labeled and packaged Sphingosomal Vinorelbine and/or Sphingosomal                Topotecan, and any component(s) thereof, used or to be used, in clinical                trials. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (l)   | “**Closing                Payment**”                means an aggregate of One Million Five Hundred Thousand Dollars                ($1,500,000 USD) in funds held in escrow to be paid by Hana to INEX                pursuant to the terms and conditions of the Transaction                Agreement. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (m)   | “**Closing                Shares**”                means the number of shares of Common Stock determined by dividing                Ten                Million Dollars ($10,000,000 USD) by the FMV of the Common Stock                as of                March 16, 2006 to be paid by Hana to INEX pursuant to the terms and                conditions of the Transaction                Agreement. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (n)   | “**Commercialize**”                and “**Commercialization**”                mean the activities customarily associated with sales of pharmaceutical                products including without limitation, DDMAC Activities, price and                reimbursement negotiations, pre-launch and launch activities, marketing,                sales, distribution, post-approval Clinical Activities, the development,                prosecution, registration and maintenance of trademarks, trade names                and                domain names, and Pharmacovigilance in each country in the                Territory. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (o)   | “**Commercially                Reasonable Efforts**”                means those efforts and resources that Hana would use were it developing,                promoting and detailing its own pharmaceutical products which are                of                similar market potential as the Products, taking into account product                labeling, market potential, past performance, economic return, the                regulatory environment and competitive market conditions in the                therapeutic area, all as measured by the facts and circumstances                at the                time such efforts are due. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (p)   | “**Common                Stock**”                means the common stock of Hana, par value $0.001 USD per                share. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------|

| (q)   | “**Confidential                Information**” means                all information, knowledge or data: |
|-----------------|-------------------------------------------------------------------------------------------------------------------------|

| (i)   | of                an intellectual, technical, scientific or industrial nature, patentable                or                otherwise, in which a Party has a proprietary or ownership interest,                including, without limitation, technical data, drawings, photographs,                scans, specifications, standards, analytical methods, techniques,                manuals,                reports, formulas, compilations, processes, information, lists, trade                secrets, computer software, programs, devices, equipment, concepts,                inventions, designs, and know-how (including the                Technology); |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | pertaining                to the business and affairs of a Party, including, without limitation,                financial information, marketing, manufacturing and commercial strategies,                patent positioning, business plans, strategies and developments,                including                any negative developments; or |
|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (iii)   | provided                or disclosed to a Party by Third Parties subject to restrictions                on use or                disclosure, whether oral or written, furnished by the disclosing                Party to                the receiving Party or any of its Representatives, whether furnished                or                prepared before or after the Effective Date of this Agreement, and                includes all analyses, compilations, data, studies, reports or other                documents based upon or including any of such information, data or                knowledge and, in all cases, all copies and tangible embodiments                thereof,                in whatever form or medium; |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (iv)   | can                be demonstrated by the receiving Party by written record to have                been                known or otherwise available to the receiving Party prior to the                disclosure by the disclosing Party; |
|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (v)   | can                be demonstrated by the receiving Party by written record to have                been in                the public domain at the time of                disclosure; |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (vi)   | after                disclosure, can be demonstrated by the receiving Party by written                record                to have subsequently become part of the public domain other than                as a                consequence of a breach of this Confidential Disclosure Agreement                by the                receiving Party or its                Representatives; |
|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (vii)   | after                disclosure, can be demonstrated by the receiving Party by written                record                to have been subsequently provided to the receiving Party by a Third                Party, but only to the extent the receiving Party can demonstrate                that                such disclosure does not violate any obligations of the Third Party                to the                disclosing Party; or |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (viii)   | the                receiving Party can demonstrate by written records results from research                and development activity conducted by the receiving Party or any                of its                Affiliates independently and in advance of disclosure by the other                Party                thereof.. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (r)   | “**Damages**”                means any losses, liabilities, obligations, damages, penalties, fines,                claims, demands, actions, suits, costs and expenses of any nature                whatsoever, excluding indirect, special or consequential damages,                but                including, without limitation, legal fees, charges and disbursements,                and                the indirect, special or consequential damages of Third Parties for                which                a Party, Hana Indemnitees or INEX Indemnitees, as the case may be,                is                responsible. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (s)   | “**Date                of Commencement**”                or “**Commencement                Date**”                means the date this Agreement will be deemed to have come into force,                which will beMay 6, 2006. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (t)   | “**DDMAC                Activities**”                mean                all activities performed in accordance with the requirements of the                Division of Drug Marketing, Advertising and Communications, Center                for                Drug Evaluation and Research of the FDA, and the Office of the Inspector                General of the Department of Health and Human Services of the United                States. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (u)   | “**Definitive                Agreements**”                mean the Asset Purchase Agreement, Elan Assignment and Novation Agreement,                License Agreement, Service Agreement, UBC Sublicense Agreement,                Transaction Agreement, and Registration Rights                Agreement. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (v)   | “**Designated                EU States**”                means any one of Germany, the United Kingdom, Italy, France or                Spain. |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|

| (w)   | “**Develop**”                and “**Development**”                means: |
|-----------------|--------------------------------------------------------------------------------------------------|

| (i)   | all                activities set forth in the Development Plan;                and |
|-----------------|-------------------------------------------------------------------------------------|

----

| (ii)   | all                activities necessary to obtain and maintain Regulatory Approvals                in each                country in the Territory, including Clinical Activities, Regulatory                Activities, Technical Transfer and Manufacturing                activities |
|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (x)   | “**Development                Plan**”                means the development plan for seeking Regulatory Approvals for each                Product in the Territory during the initial twelve (12) months following                the Effective Date, together with a corresponding budget accounting                for                the anticipated costs to be expended or incurred by Hana in conducting                the                Development. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (y)   | “**Discloser**”                means a Party to this Agreement providing its Confidential Information                to                the other Party as Recipient. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (z)   | “**Discontinued                Patent**”                shall have the meaning set forth in Section 6.8(c). |
|-----------------|-------------------------------------------------------------------------------------------------------------------------|

| (aa)   | “**$                USD**”                and “**US                Dollars**”                shall mean the lawful money of the United States of America, to be                used                for payments due to INEX. |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (bb)   | “**$                CDN**”                and “**Canadian                Dollars**”                shall mean the lawful money of Canada to be used for payments due                to the                University. |
|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (cc)   | “**Effective                Date of Termination**”                means the date on which this Agreement is terminated pursuant to                Article                17. |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (dd)   | “**Excess                Amount**”                shall have the meaning set forth in Section 7.5(g). |
|------------------|-------------------------------------------------------------------------------------------------------------------|

| **(ee)  ** | **“Fair                Market Value**”                for the purposes of Sections 1.1(fff)                and 1.1(kkkk),                means the highest price, expressed in dollars, that an asset (whether                tangible or intangible) would bring in an open and unrestricted market,                between a willing buyer and a willing seller who are both knowledgeable,                informed, and prudent, and who are acting independently of each                other. |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ff)   | “**FDA**”                means the Food and Drug Administration of the United States of                America. |
|------------------|-----------------------------------------------------------------------------------------------------------------------------|

| (gg)   | “**FTE                Rate**”                means the fully burdened rate established by INEX for the services                of an                INEX employee or consultant providing IP Services which for the first                year                of this Agreement, is $[***]                USD                based on 1,800 employee hours per year, or pro-rata portion thereof;                provided however, that on each anniversary of the Effective Date,                the FTE                Rate shall be adjusted by a percentage equal to the net change in                the                Consumer Price Index (All Items) for the province of British Columbia                for                the twelve (12) month period ending with December of the calendar                year                immediately preceding such anniversary                date. |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (hh)   | “**FMV**”                means the quotient resulting from dividing (A) the sum of the value                of all                trades for each of the twenty (20) trading days immediately preceding                the                FMV reference date, by (B) the aggregate volume of all trades of                shares of                Common Stock during such twenty trading day period, in each case                as                reported in the principal exchange or stock market on which the Common                Stock is then listed. |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | “**GCP                Requirements**”                or “**Good                Clinical Practices**”                means the then current standards for clinical trials for pharmaceuticals                as required by the FDA, the TPD and the equivalent Regulatory Authority                elsewhere in the Territory, and as applicable, the policies and guidelines                of the International Conference on Harmonization in effect for the                clinical testing of pharmaceutical                materials. |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (jj)   | “**GLP                Requirements**”                or “**Good                Laboratory Practices**”                means the current Good Laboratory Practices standards required by                the FDA,                the TPD and the equivalent Regulatory Authority elsewhere in the                Territory                in effect for the testing of pharmaceutical materials as applied                to raw                materials and finished products. |
|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (kk)   | “**Hana                Field**”                means all uses of the Product. |
|------------------|-------------------------------------------------------------------------------------------|

| (ll)   | “**Hana                Indemnitees**”                shall have the meaning set forth in Section 8.2 |
|------------------|------------------------------------------------------------------------------------------------------------------|

| (mm)   | “**Hana                Intellectual Property**”                means: |
|------------------|-----------------------------------------------------------------------------------|

| (i)   | all                Intellectual                Property Rights, patents                and patent applications (whether complete or incomplete or whether                filed                or unfiled) including                registrations, in any jurisdiction world-wide, as well as any patents                and                patent applications                assigned to or                licensed by Hana from INEX and Third Parties during the Term of                this Agreement;                and |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | All                Confidential                Information owned                or controlled by Hana at any time during the Term of this                Agreement. |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (nn)   | “**Human                Clinical Trials**”                shall have the meaning set forth in Section 12.1(a). |
|------------------|----------------------------------------------------------------------------------------------------------------------------|

| (oo)   | “**Improvements**”                shall have the meaning set forth in Section 6.5. |
|------------------|------------------------------------------------------------------------------------------------|

| (pp)   | “**IND**”                means an Investigational New Drug application in accordance with                the rules                and regulations of the FDA. |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (qq)   | “**Indemnitee**”                shall have the meaning set forth in Section 8.4. |
|------------------|----------------------------------------------------------------------------------------------|

| (rr)   | “**Indemnitor**”                shall have the meaning set forth in Section 8.4. |
|------------------|----------------------------------------------------------------------------------------------|

| (ss)   | “**INEX                Indemnitees**”                shall have the meaning set forth in Section 8.3. |
|------------------|-------------------------------------------------------------------------------------------------------------------|

| (tt)   | “**Information**”                means any and all Technology, the terms and conditions of this Agreement,                and any and all oral, written, electronic or other communications                and                other information disclosed or provided by the Parties including                any and                all analyses or conclusions drawn or derived therefrom regarding                this                Agreement and information developed or disclosed hereunder, or any                Party’s                raw materials, processes, formulations, analytical procedures,                methodologies, products, samples and specimens or                functions. |
|------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (uu)   | “**Intellectual                Property Rights**”                means all                intellectual property rights subject to protection by intellectual                property laws in any country of the world, arising under statutory                or                common law, contract, or otherwise, and whether or not perfected,                including without limitation, all (a) patents, reissues of and re-examined                patents, and patent applications, whenever filed and wherever issued,                including without limitation, continuations, continuations-in-part,                substitutes and divisions of such applications and all priority rights                resulting from such applications; (b) rights associated with works                of                authorship including without limitation copyrights, moral rights,                copyright applications, copyright registrations, synchronization                rights,                mask work rights, mask work applications, mask work registrations;                (c)                rights associated with trademarks, service marks, trade names, logos,                trade dress, goodwill and the applications for registration and                registrations thereof; (d) rights relating to the protection of trade                secrets and confidential information; (e) rights analogous to those                set                forth in this Section and any and all other proprietary rights relating                to                intangible property; and (f) divisions, continuations, renewals,                reissues                and extensions of the foregoing (as and to the extent applicable)                now                existing, hereafter filed, issued or acquired. |
|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (vv)   | “**IP                Committee**”                shall have the meaning set forth in Section 6.1. |
|------------------|---------------------------------------------------------------------------------------------------------------|

| (ww)   | “**IP                Services**”                means                services that Hana deems reasonably necessary, desirable or helpful                to                evidence, maintain, protect or enforce Hana’s rights as set forth under                the Services Agreement. |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (xx)   | “**License                Agreement**”                shall mean the License Agreement between the Parties dated May 6,                2006. |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|

| (yy)   | “**Litigating                Party**”                shall have the meaning set forth in Section 7.5(e). |
|------------------|----------------------------------------------------------------------------------------------------------------------|

| (zz)   | “**Major                Markets**”                means the countries of the United States of America, Germany,                the United Kingdom, Italy, France, Spain. |
|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (aaa)   | “**Manufacture**”                means all or a portion of the activities of Hana, INEX its Affiliates                or                their respective Third Party contractors associated with the                manufacturing, filling, sampling, testing, handling, labeling, packaging                and storage of Material and all work-in-progress. “Manufacturing” and                “Manufactured” will have comparable                meanings.” |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (bbb)   | “**Material**”                means all compounds, materials, substances, components or consumables                sourced or Manufactured by INEX, Hana or any of their respective                Third                Party contractors to produce Clinical Trial Material, and Product                for                commercial sale, but excluding machinery and                equipment. |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ccc)   | “**Maximum                Issuance Amount**”                shall have the meaning set forth in Section 5.7(d). |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------|

| (ddd)   | “**Method                Transfer**”                means, in respect of the Services, the transfer by INEX and/or INEX’s                Third Party contractors to Hana, Hana’s Third Party contractors and/or                INEX’s Third Party contractors, of the methods for the testing of Material                pursuant to Method Transfer protocols mutually agreed between the                Parties,                and shall include without limitation, the performance of Method Transfer                qualification. |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (eee)   | “**NDA**”                means a New Drug Application in accordance with the rules and regulations                of the FDA. |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------|

| (fff)   | “**Net                Sales**”                means the aggregate US Dollar equivalent of gross revenues invoiced                by                Hana and its Affiliates and Sublicensees from or on account of the                sale of                Product to Third Parties, in any given calendar year, less deductions                actually allowed or specifically allocated to Product and actually                incurred by Hana using US GAAP and reasonable practices with respect                to                sales of all Product, consistently applied, for the                following: |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | credits                or allowances, if any, actually granted on account of recalls, rejection                or return of Product; |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | insurance,                freight or other transportation costs incurred in shipping Product                to such                Third Parties; and |
|------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (iii)   | excise                taxes, sales taxes, value added taxes, consumption taxes, customs                and                other duties or other taxes or other governmental charges imposed                upon and                paid or allowed with respect to the production, importation, use                or sale                of Product (excluding income or franchise taxes of any                kind); |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Permitted      Deductions**

| (iv)   | no                deductions shall be made for any item of cost incurred by Hana, its                Affiliates or Sublicensees in preparing, Manufacturing, shipping                or                selling Product except as permitted pursuant to Sections 1.1(fff)(i),                1.1(fff)(ii)                and 1.1(fff)(iii)                inclusive; |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (v)   | Net                Sales shall not include transfer between any of Hana and any of its                Affiliates or Sublicensees for resale, but Net Sales shall include                the                subsequent final sales to Third Parties by such Affiliates or                Sublicensees; |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (vi)   | fair                market value shall be assigned to any and all non-cash consideration                such                as but not limited to any credit, barter, benefit, advantage or concession                received by Hana or its Affiliates or Sublicensees in payment for                sale of                Product; |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (vii)   | as                used in this definition, a “sale” shall have occurred when Product are                billed out or invoiced; |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------|

| (viii)   | notwithstanding                anything herein to the contrary, the following shall not be considered                a                sale of Product under this                Agreement: |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (A)   | the                transfer of a Product to a Third Party without consideration to Hana                in                connection with the development or testing of a Product;                or |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (B)   | the                transfer of a Product to a Third Party without consideration in connection                with the marketing or promotion of the Product (eg.                samples). |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ggg)   | “**Non-Abandoning                Party**”                shall have the meaning set forth in Section 6.8(a). |
|-------------------|--------------------------------------------------------------------------------------------------------------------------|

| (hhh)   | “**Non-Competition                Terms**”                means the Non-Competition Terms contained in the Transaction Agreement                between the Parties dated May 6. |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (iii)   | “**Non-litigating                Party**”                shall have the meaning set forth in Section 7.5(e). |
|-------------------|--------------------------------------------------------------------------------------------------------------------------|

| (jjj)   | “**Notice                of Abandonment**”                shall have the meaning set forth in Section 6.8(a). |
|-------------------|---------------------------------------------------------------------------------------------------------------------------|

| (kkk)   | “**Objectionable                Material**”                shall have the meaning set forth in Section 9.3(b). |
|-------------------|----------------------------------------------------------------------------------------------------------------------------|

| (lll)   | “**Party**”                means Hana or INEX and “**Parties**”                means Hana and INEX. |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------|

| (mmm)   | **“Patent(s)**”                mean all Valid Claims of the following intellectual                property: |
|-------------------|-------------------------------------------------------------------------------------------------------------------------|

| (i)   | the                Canadian, United States and foreign patents and/or patent applications                listed in **Schedule**                "**A**"; |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | Canadian,                United States and foreign patents issued from the applications listed                in                **Schedule**                "**A**"                and from any and all divisionals and continuations of these                applications; |
|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (iii)   | claims                of Canadian, United States and foreign continuation-in-part applications                and of the resulting patents, which are directed to subject matter                specifically described in the Canadian, United States, and foreign                applications listed in **Schedule**                "**A**"; |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (iv)   | claims                of all foreign patent applications, and of the resulting patents,                which                are directed to subject matter specifically described in the Canadian                and                United States patents and/or patent applications described in (i),                (ii) or                (iii) above; and |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (v)   | any                reissues of United States, Canadian or foreign patents described                in (i),                (ii), (iii) or (iv) above. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------|

| (nnn)   | “**Person**”                means and includes any individual, corporation, partnership, firm,                joint                venture, syndicate, association, trust, government body, Affiliates,                Third                Parties and any other form of entity or                organisation. |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ooo)   | “**Pharmacovigilance**”                means all the activities associated with maintaining an effective                drug                safety monitoring system and adverse events reporting system in compliance                with the requirements of Regulatory                Authorities. |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ppp)   | “**Prime                Rate**”                means the prime or equivalent rate quoted by the Bank of Canada from                time                to time. |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (qqq)   | “**Product**”                means any one or more of Sphingosomal Vinorelbine and Sphingosomal                Topotecan. |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------|

| (rrr)   | “**QA**”                means Quality Assurance, being that part of each management system,                within                Hana and INEX separately, having responsibility for assuring the                quality                of Material and Manufacturing in respect of compliance with Regulatory                Requirements. |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (sss)   | “**QC**”                means Quality Control, being that part of each management system,                within                Hana and INEX separately, having responsibility for quality control                testing of Material in respect of compliance with Regulatory                Requirements. |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ttt)   | “**Recipient**”                means a Party to this Agreement receiving Confidential Information                of the                other Party as Discloser. |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (uuu)   | “**Registrational                Clinical Trial**”                means any one of a Phase III clinical trial or pivotal Phase II clinical                trial conducted in furtherance of Regulatory                Approvals. |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (vvv)   | “**Regulatory                Authorities**”                means the FDA and any other like governmental authorities, whether                federal, provincial, state or municipal, regulating the manufacture,                importation, distribution, marketing, clinical testing and/or sale                of                therapeutic substances in the                Territory. |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (www)   | “**Regulatory                Approvals**”                means all necessary and appropriate regulatory approvals which must                be                obtained before placing each Product on the market in any country                in the                Territory in which such approval is required, including without                limitation, INDs, NDAs, and any other comparable terms as applicable                with                regard to any such approvals in any other country in the                Territory. |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (xxx)   | “**Regulatory                Requirements”**means                Applicable Laws and all rules, regulations and guidances in respect                of QC                and QA procedures and processes, manufacturing and production batch                records (including the master production record), packaging, handling,                storage, delivery and retention of raw material and finished product                samples and associated support data, and all licenses, certificates,                authorizations or requirements from Regulatory Authorities in the                Territory, including but not limited to cGMP Requirements in respect                of                the Manufacture of Material. |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (yyy)   | “**Regulatory                Submission**”                means any submission or filing made in furtherance of obtaining and                maintaining any Regulatory                Approvals. |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (zzz)   | “**Representatives**”                means, in respect of a Person, that Person’s Affiliates and their                respective directors, officers, employees, consultants, subcontractors,                sublicensees (including Sublicensees), agents, representatives and                other                persons acting under their                authority. |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (aaaa)   | “**Revenue                Due UBC**”                means all revenues, receipts, monies, and the fair market value of                all                other consideration collected or received by Hana or its Affiliates                from a                Sublicensee or other Third Party, whether by way of cash or credit                or any                barter, benefit, advantage, or concession, (but not including Sublicensing                Revenue Due UBC) from the marketing, manufacturing, sale, distribution,                or                use, of the Technology and/or any Product in any or all parts of                the world                where Hana is permitted by law and this Agreement to market, Manufacture,                sell, distribute or use the Technology and/or any Product, in such                national jurisdictions where a Valid Claim subsists, on a country                by                country basis, less the following deductions to the extent included                in the                amounts invoiced and thereafter actually allowed and                taken: |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | credit,                allowances or refunds given on account of returned                Products; |
|-----------------|----------------------------------------------------------------------------------------------------|

| (ii)   | transportation                charges invoiced separately and actually charged to Third                Parties; |
|------------------|-----------------------------------------------------------------------------------------------------------------|

| (iii)   | taxes,                duties and customs on all sales of                Product; |
|-------------------|----------------------------------------------------------------------------------|

| (iv)   | agents’                commissions paid by Hana for the sale of Product;                and |
|------------------|---------------------------------------------------------------------------------------------------|

| (v)   | bona                fide special rebates provided by Hana for Product purchased by Third                Parties. |
|-----------------|------------------------------------------------------------------------------------------------------------------|

| (bbbb)   | “**Royalties**”                means Royalty Due UBC, Royalty Due INEX, and Sublicensing Revenue                Due                INEX. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|

| (cccc)   | “**Royalty                Due Dates**”                means the last working day of March, June, September and December                of each                and every year during which this Agreement remains in full force                and                effect. |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (dddd)   | “**Royalty                Due INEX**”                means the royalty payable to INEX on Net Sales in the Territory as                set                forth in Section 5.7,                but excluding Sublicensing Revenue Due                INEX. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (eeee)   | “**Royalty                Due UBC**”                means the royalties payable to UBC on Revenue Due UBC and Sublicensing                Revenue Due UBC. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ffff)   | “**Service                Agreement**”                means the Service Agreement entered into between INEX and Hana dated                effective May 6, 2006. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (gggg)   | “**Sphingosomal                Topotecan**”                means a liposome that includes sphingomyelin and cholesterol and                contains                encapsulated topotecan, wherein the sphingomyelin comprises less                than 20%                dihydrosphingomyelin. |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (hhhh)   | “**Sphingosomal                Vinorelbine**”                means a liposome that includes sphingomyelin and cholesterol and                contains                encapsulated vinorelbine, wherein the sphingomyelin comprises less                than                20% dihydrosphingomyelin. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (iiii)   | “**Sublicense                Agreement**”                means an agreement between Hana or its Affiliate and a Sublicensee                to whom                Hana has granted a further sub-sublicense of the rights granted to                Hana                hereunder. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (jjjj)   | “**Sublicensee**”                means a Person to whom Hana or its Affiliate have granted a Sublicense                Agreement of the rights granted to Hana hereunder. |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (kkkk)   | "**Sublicensing                Revenue Due INEX**"                means                all transaction closing payments, milestone payments, license fees                and any                other pre-Commercialization                payments (excluding royalties, sales revenue, sales commissions and                any                monies and proceeds derived from the sale of sublicensed Product)                payable                to, collected or received by Hana or its Affiliates pursuant to each                Sublicense Agreement entered in respect of the Technology granted                hereunder. Except as otherwise expressly provided below, “Sublicensing                Revenue Due INEX” shall not                include: |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | loans                to Hana or its Affiliate by a Sublicensee relating to the Technology,                except to the extent that the interest charged for such loan is less                than                Fair Market Value (in which case only such difference between the                interest                rate charged to Hana and the interest rate at Fair Market Value shall                constitute Sublicensing Revenue Due INEX) or to the extent that the                principal of a loan is forgiven (in which case only such forgiven                amount                shall constitute Sublicensing Revenue Due INEX);                or; |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | equity                investments in Hana by a Sublicensee or equity of the Sublicensee                relating                to the Technology, except to the extent that such investments are                made at                greater than Fair Market Value (in which case only the excess premium                shall constitute Sublicensing Revenue Due INEX). For the purposes                of this                subsection, if the shares of either Hana or its Sublicensee are not                listed                on any stock exchange, the Fair Market Value shall be based on the                price                at which shares of either Hana or its Sublicensee, as the case may                be,                have been issued to investors (who are not industry-related strategic                investors or collaborative research partners) in the then most recent                bona                fide arm’s length private placement financing completed within the                preceding twelve (12) months having gross proceeds of at least Ten                Million                Dollars ($10,000,000). If no such private placement financing has                been                completed, the Parties shall appoint a mutually acceptable Person                as an                independent evaluator, and if the Parties cannot agree on an evaluator,                the Fair Market Value shall be determined as provided in Section                14.3; |
|------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (iii)   | An                exchange of rights, assets, liabilities or other interest of any                kind,                except to the extent that the economic benefit conferred upon Hana                or its                Affiliates by reason of such exchange exceeds the Fair Market Value                of the                consideration which would have been paid by Hana or its Affiliates                for                such rights, assets, liabilities or interests, as determined by:                (i) the                mutual agreement of the Parties following the application of U.S.                GAAP, or                failing mutual agreement; (ii) the binding decision of a mutually                appointed independent Third Party banker or valuator familiar with                the                pharmaceutical industry. |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (llll)   | “**Sublicensing                Revenue Due UBC**”                means all revenues, receipts, monies, milestone payments and research                fees                (in respect of either milestone payments or research fees, only to                the                extent that same are in excess of reimbursement for the direct costs                of                research and development or pursuit of Regulatory Approvals undertaken                by                Hana or its Affiliates pursuant to a written research or development                plan), payments, royalties, license fees and the fair market value                of all                other consideration collected or received by Hana or its Affiliates                whether by way of cash, or credit or any barter, benefit, advantage,                or                concession pursuant to each Sublicense                Agreement                relating to Valid Claims which form a part of the Technology and/or                any                Product (but not including Revenue Due UBC).                Where any Sublicensing Revenue Due UBC is derived from a country                other                than the U.S. it shall be converted to the equivalent in U.S. Dollars                on                the date Hana is deemed to have received such Sublicensing Revenue                Due UBC                pursuant to the terms hereof at the rate of exchange set by Federal                Reserve Bank of New York for buying such currency. The amount of                U.S.                Dollars pursuant to such conversion shall be included in the Sublicensing                Revenue Due UBC.] |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (mmmm)   | “**Technical                Transfer**”                means the transfer by INEX and/or INEX’s Third Party contractors to Hana,                Hana’s Third Party contractors and/or INEX’s Third Party contractors of                those aspects of the know-how encompassed by the Technology necessary                and                useful for the Manufacture of Material, and includes Method                Transfer. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (nnnn)   | “**Technology**”                means the Patent(s) and any and all knowledge, know-how and/or technique                or techniques invented, developed and/or acquired, being invented,                developed and/or acquired by the University solely or jointly with                INEX                relating to the Patent(s) as listed in **Schedule**                "**A**"                hereto, as amended from time to time, including, without limitation,                all                research, data, specifications, instructions, manuals, papers or                other                materials of any nature whatsoever, whether written or otherwise,                relating                to same. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (oooo)   | “**Term**”                shall have the meaning set forth in Section 16.1. |
|--------------------|-----------------------------------------------------------------------------------------|

| (pppp)   | “**Territory**”                means all of the countries and territories of the world. |
|--------------------|-----------------------------------------------------------------------------------------------------|

| (qqqq)   | “**Third                Party(ies)**”                means any Person(s) other than Hana or INEX or any of their respective                Affiliates. |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (rrrr)   | “**UBC**”                and “**University**”                each mean the University of British                Columbia. |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (ssss)   | “**UBC                Consent**”                means the consent agreement executed by the University, INEX and                Hana                dated May 6, 2006. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (tttt)   | “**UBC                License**”                means the License Agreement between INEX and the University dated                effective July 1, 1998 |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (uuuu)   | “**UBC                Trade-marks**”                means any mark, trade-mark, service mark, logo, insignia, seal, design,                symbol, or device used by the University in any manner                whatsoever. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (vvvv)   | “**University                Indemnified Parties**”                shall have the meaning set forth in Section 8.1(a). |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------|

| (wwww)   | “**US                GAAP**”                means generally accepted accounting principles applied in the United                States of America. |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (xxxx)   | “**Valid                Claim**”                means either: |
|--------------------|---------------------------------------------------------------------------|

| (i)   | a                claim of an issued and unexpired patent which has not been held                unenforceable, unpatentable or invalid by a court or other governmental                agency of competent jurisdiction, and which has not been admitted                to be                invalid or unenforceable through reissue, disclaimer or otherwise;                or |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | a                claim in a patent application, provided that if such pending claim                has not                issued as a claim of an issued patent within seven (7) years after                the                filing date of such patent application, such pending claim shall                not be a                Valid Claim for purposes of this                Agreement. |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**1.2  **
**Other        Definitions**

**Article      2**
** **
**PROPERTY      RIGHTS IN AND TO THE TECHNOLOGY**

**2.1  **
**University’s        Intellectual Property Rights**

| (a)   | The                Parties hereto hereby acknowledge and agree that the University owns                any                and all right, title and interest in and to the                Technology. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | Hana                shall, at the written request of INEX, enter into such further agreements                and execute any and all documents as may be required to ensure that                ownership of the Technology remains with the                University. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | On                the last working day of June of each and every year during which                this                Agreement remains in full force and effect, each of Hana and INEX                shall                deliver in writing to UBC, the details of any Patents filed by each                of                them during the previous twelve month period. The delivery of reports                required pursuant to this Section 2.1(c)                is                separate and distinct from the reporting requirements established                between                each of Hana and INEX as set forth in Sections 6.6                and 6.7. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**Article      3**
** **
**GRANT      OF SUBLICENCE**
**      TO HANA**

**3.1  **
**Sublicense        Grant**
**        To Hana**

| (a)   | In                consideration of the Royalties reserved herein, the covenants of                Hana                contained herein, and subject to the terms of this Agreement, INEX                hereby                grants to Hana and Hana hereby accepts an exclusive sublicense under                the                Technology to make, have made, use, sell, offer for sale, sublicense,                distribute, import, and have imported Product in the Hana Field in                the                Territory. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | It                is understood and agreed that the foregoing exclusive sublicenses                grant to                Hana the rights enumerated to the exclusion of all other parties,                including INEX and its Affiliates. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | It                is also understood that INEX retains exclusive rights under the Technology                outside the Hana Field. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------|

| (d)   | Hana                shall not sublicense or cross-license the Technology without the                prior                written consent of the University. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (e)   | Notwithstanding                Section 3.1(a)                and (b) herein, the Parties acknowledge and agree that INEX and the                University may each use the Technology without charge in any manner                whatsoever for non-commercial research, scholarly publication,                educational, or other non-commercial                use. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**3.2  **
**License        Grant to INEX**

| (a)   | Hana                hereby grants to INEX a non-exclusive license under the Technology                to                make, have made, use, import and have imported Products solely for                non-commercial research, scholarly publication, education, or other                non-commercial purposes. |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | Hana                hereby grants to INEX a non-exclusive license under                the Technology to carry out INEX’s activities under the Development Plan                and Services Agreement. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | Hana                hereby grants to INEX a worldwide, royalty-free, non-exclusive license                under the                Hana Intellectual Property to                make, have made, use, sell, offer for sale, import, and have                imported                liposomal drug products outside the Hana                Field. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**3.3  **
**Compliance        with UBC License**

**3.4  **
**Payment        of Taxes**

----

**Article      4**
** **
**SUBLICEN**
**SING      BY HANA**

**4.1  **
**UBC        Consent**

**4.2  **
**Sublicenses        to Affiliates**

| (a)   | Hana                will cause the Affiliate so sublicensed to perform the terms of this                Agreement as if such Affiliate were Hana                hereunder; |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | any                Affiliate so sublicensed shall unconditionally, absolutely and irrevocably                covenant and agree with INEX and the University as primary obligor,                to                adopt as its own obligations every obligation of Hana contained or                set                forth in this Agreement to the extent pertinent to the scope of such                sublicense, including without limitation, the covenants in this Agreement                to pay any amounts due to the University and to INEX under the terms                of                this Agreement; and |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | Hana                unconditionally guarantees the performance of each Affiliate hereunder                as                if they were signatories to this Agreement to the extent the performance                or lack of performance is a breach of this                Agreement. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (d)   | the                obligations and liabilities of such Affiliate and Hana under this                Agreement shall be joint and several and INEX shall not be obliged                to seek                recourse against an Affiliate before enforcing its rights against                Hana.                For greater certainty it is hereby confirmed that any default or                breach by                an Affiliate of Hana of any term of this Agreement will also constitute                a                default by Hana under this Agreement, provided, however, that Hana                shall                be entitled to written notice of any claimed default, and shall have                ninety (90) days following receipt of such notice in which to cure                any                such default pursuant to Section 17.4                hereof. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**4.3  **
**Furnish        Sublicense Pre and Post Execution**

| (a)   | At                least thirty (30) days prior to an anticipated execution, Hana will                furnish the University with a copy of each Sublicense Agreement which                Hana                proposes to execute so as to allow the University time to review                and                comment. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | Hana                will furnish each of INEX and the University with a copy of each                such                Sublicense Agreement granted within thirty (30) days after                execution. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**4.4  **
**Covenants        by Hana’s Sublicensee**

----

**4.5  **
**Covenants        by Hana**

| (a)   | Hana                unconditionally guarantees the performance of each Affiliate hereunder                as                if they were signatories to this Agreement to the extent the performance                or lack of performance is a breach of this                Agreement. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | Each                Sublicense Agreement shall contain covenants by the Sublicensee for                the                benefit of INEX to observe and perform similar terms and conditions                to                those in this Agreement. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|

| (c)   | All                      Sublicense Agreements granted by Hana shall be further sublicensable                      or                      assignable with the prior written consent of the University,                      but without                      the prior written consent of INEX; provided, however, that                      Hana shall not                      sublicense any rights granted herein to any Person that in                      whole or in                      part, either alone or in partnership, in collaboration or in                      conjunction                      with any Person other than INEX, whether as principal, agent,                      employee,                      director, officer, shareholder, licensor or in any capacity                      or manner                      whatsoever, whether directly or indirectly manufactures liposomal                      products                      without first either: (i)                      obtaining INEX’s written consent; or (ii)including in such                      Sublicense Agreement a                      provision requiring the Sublicensee to agree that                      it will not use the Technology for any purpose other than the                      Development                      or Commercialization                      of Products. |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|
| (d)   | In                the event that Hana becomes aware of a material breach of any such                Sublicense Agreement by a Sublicensee, Hana shall promptly notify                INEX of                the particulars of same and take all commercially                reasonable steps to enforce the terms of such Sublicense                Agreement. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (e)   | Within                ten (10) Business Days after execution of a Sublicense Agreement,                Hana                shall provide INEX with a copy thereof (provided that Hana shall                be                permitted to redact the financial terms of such                agreement). |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (f)   | All                Sublicense Agreements shall terminate upon the termination of Hana’s                rights granted herein unless events of default are cured by Hana                or its                Sublicensee within the period for the cure of default after notification                by INEX as provided by the terms of this                Agreement. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (g)   | Any                Sublicensee who wishes to grant a further sublicense shall comply                with the                terms of this Section as if the further sublicense were a sublicense                hereunder, including providing to INEX, Hana and the University the                information described in this Section, and obtaining the consent                of the                University referred to in this Section, prior to any execution of                any such                sub-sub-sublicense. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (h)   | All                Sublicense Agreements shall include an obligation for each Sublicensee                to                account for and report its sales of Product on the same basis as                if such                sales were sales of Hana, and INEX and the University shall receive                compensation in the same amounts as if the sales of Product by the                Sublicensee were sales of Hana; and |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | Hana                shall remain responsible to INEX for the compliance of each Sublicensee                with the financial and other obligations due under this                Agreement. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (j)   | With                respect to the licenses granted to INEX under Section 3.2,                INEX shall have the right to grant sublicenses to its Affiliates                and to                Third Parties. All sublicenses will be consistent with the terms                of this                Agreement,                shall not relieve Hana or INEX of their obligations hereunder,                and shall incorporate terms and conditions for Hana’s benefit comparable                to those set forth in this Section 4.4                applicable to sublicenses granted by Hana. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**4.6  **
**Covenants        by Hana’s Sublicensee**

**4.7  **
**Confirmation        from the University**

| (a)   | the                UBC License provides that Hana may request from the University, following                the receipt of the UBC Consent, a letter confirming that if the                University: |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | gives                notice of default to INEX pursuant to Article 17.3 of the UBC License,                or |
|-----------------|---------------------------------------------------------------------------------------------------------------|

| (ii)   | takes                any other action pursuant to Article 17.1 or 17.2 of the UBC License                to                terminate the UBC License, |
|------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|

*mutatis      mutandis*

| (b)   | if                the UBC License is terminated, and provided that this Agreement is                in good                standing at such time: |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | the                terms and conditions of the UBC Consent shall apply;                or |
|-----------------|-------------------------------------------------------------------------------------------|

| (ii)   | in                the event that the terms and conditions of the UBC Consent do not                apply,                or otherwise at the option of Hana, the University and Hana may enter                into                good faith negotiations for the grant to Hana of a new license                substantially on the same terms and conditions as are contained in                the UBC                License. |
|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Article      5**
** **
**ROYALTIES      AND CONSIDERATION**

**5.1  **
**Assumption        of Royalty Obligations**

| (a)   | As                a condition of the grant of the sublicence by INEX to Hana of the                Technology, Hana shall assume and perform all payment obligations                of INEX                to the University set forth in the UBC License including all interest                and                taxes attributable thereto, arising from Hana and/or its Sublicensee(s)’                use of the Technology within the Hana Field. Without limiting the                generality of the foregoing, Hana shall assume and perform all obligations                as set forth in Sections 5.2,                5.3,                5.4,                5.5,                5.6,                and 18.1(d)                in                this Agreement. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | For                avoidance of doubt, the obligations of Hana under Section 5.1(a)                are in addition to and not in substitution of any other                obligations                set forth in this Article                5. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**5.2  **
**Royalty        **
**Due        UBC**

| (a)   | Hana                covenants to pay directly to the University a royalty (the “**Royalty                Due UBC”**): |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------|

| (i)   | on                all Revenue Due UBC, calculated in accordance with the percentages                set out                in the “**Royalty                Due UBC**”                Column of **Schedule                “A”**;                and |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | on                all Sublicensing Revenue Due UBC, calculated in accordance with the                percentages set out in the “UBC Sublicense Royalty” Column of**Schedule “A”**; |
|------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Schedule**
**A**
**Schedule**
**B**

**5.3        **
**Rates      Established by UBC License**

**Schedule**
**A**
**Schedule**
**B**
** **

**5.4        **
**One      Royalty Per Product Payable**
**      to UBC**

| (a)   | if                more than one Patent sublicensed under this Agreement is required                in                respect of a Product, then the royalty applicable to any such specific                Product pursuant to Section 5.2                hereof may be reduced such that there shall only be one royalty payable                on                such Product and that royalty shall be the Royalty Due UBC for one                of the                Patents used (determined in accordance with Section 5.2                and **Schedule**“**B**”)                which is most favourable to the University;                and |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | if                it is reasonably commercially necessary for a Product to be subject                to                royalty obligations to one or more Third Parties other than the                University, or if Hana licenses or owes a royalty in respect of one                or                more patents from one or more Third Parties to be used in combination                with                the Patents sublicensed hereunder, then the Royalty Due UBC set out                in                Section 5.2                shall be adjusted by apportioning the relative value between the                Technology and said Third Party patent(s) by multiplying the Royalty                Due                UBC by the formula a/(a+b) where "a" is the value of the Patent                sublicensed under this Agreement, and "b" is the value of the Third                Party                patent(s), provided that "b" shall never be fixed at a value higher                than                "a". Values "a" and "b" shall be determined on the basis of the values                of                each patent when used separately and not used in combination with                each                other. If the Parties are unable to come to agreement on said respective                values, the issue will be determined by arbitration pursuant to                14.3                For greater certainty, notwithstanding anything in this Section,                the final                Royalty Due UBC payable by Hana to the University shall not be less                than                [***]%                of the Royalty Due UBC determined in accordance with Section 5.2. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**5.5        **
**Payment      of Royalty Due UBC**

| (a)   | The                Royalty Due UBC shall become due and payable by Hana to the University                within thirty (30) days of each respective Royalty Due Date and shall                be                calculated with respect to the Revenue and the Sublicensing Revenue                Due                UBC in the three (3) month period immediately preceding the applicable                Royalty Due Date. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | All                payments of Royalty Due UBC made by Hana to the University hereunder                shall                be made in U.S. Dollars without any reduction or deduction of any                nature                or kind whatsoever, except as may be prescribed by                law. |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | Revenue                Due UBC shall be deemed to have been received by Hana or any Affiliate                of                Hana when actually received, provided that diligent efforts short                of                commencing legal action are made to collect same. Sublicensing Revenue                Due                UBC shall be deemed to have been received by Hana or any Affiliate                of Hana                with respect to each of their Sublicensees when such consideration                is                actually received. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (d)   | Any                transaction, disposition, or other dealing involving the Technology,                Product or any part thereof between Hana and another Person that                is not                made at fair market value shall be deemed to have been made at fair                market                value, and the fair market value of that transaction, disposition,                or                other dealing shall be deemed to be part of the Revenue (or the                Sublicensing Revenue Due UBC, as the case may be) and shall be included                in                the calculation of Royalty Due UBC under this                Agreement. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (e)   | Revenue                Due UBC shall not include and no Royalty Due UBC will be payable                on                Product used for research and development of the Product or the Technology                for which Hana does not receive consideration, such as but not limited                to                dispositions for clinical trials, marketing, research use and                compassionate use or for other similar                uses. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (f)   | Sublicensing                Revenue Due UBC shall not include and no Royalty Due UBC will be                payable                on: |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | loans                to Hana by a Sublicensee relating to the Technology except to the                extent                that the interest charged for same is less than fair market value                (in                which case such difference shall be Sublicensing Revenue Due UBC)                or to                the extent that the principal of same is forgiven (in which case                such                forgiven amount shall be Sublicensing Revenue Due UBC);                or |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | investments                in Hana by a Sublicensee relating to the Technology except to the                extent                that such investments are made at greater than fair market value                (in which                case such premium shall be Sublicensing Revenue Due UBC). For the                purposes                of this Section, if the shares are not listed on any stock exchange,                the                fair market value shall be based on the price at which shares have                been                issued to investors (who are not industry-related strategic investors                or                collaborative research partners) in the then most recent bona fide                arm’s                length private placement financing completed within the preceding                twelve                (12) months having gross proceeds of at least $500,000 CDN. If no                such                private placement financing has been completed, the Parties hereto                shall                appoint a mutually acceptable Person as an independent evaluator                and if                the Parties cannot agree on an evaluator, the appointing authority                shall                be the British Columbia International Commercial Arbitration Centre. |
|------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (g)   | If                at any time, a Third Party in any country shall, under the right                of a                compulsory license granted or ordered to be granted by a competent                governmental authority, manufacture, use or sell any Product with                respect                to which Royalty Due UBC would be payable pursuant to this Agreement,                then                Hana may reduce the Royalty Due UBC on sales in such country of such                Product to an amount no greater than the amount payable by said Third                Party to Hana as consideration for the compulsory                license. |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (h)   | No                Royalty Due UBC shall be payable on the sales of Product between                Hana and                its Affiliates, provided that Royalty Due UBC shall be payable on                all                Revenue received by Hana or its Affiliate(s) from any subsequent                sale of                such Product to a Sublicensee or to a Third                Party. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | No                Royalty Due UBC shall be payable to the University on any revenue                paid to                Hana by its Affiliates as a consequence of a sublicense between Hana                and                its Affiliates, but Royalty Due UBC shall be payable on all Revenue                Due                UBC paid to Hana’s Affiliates by a Third Party as a consequence of a                sublicense between Hana’s Affiliates and any Third                Party. |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (j)   | If,                at any time, legal restrictions prevent the prompt remittance of                part or                all of the Royalty Due UBC with respect to any country where Revenue                Due                UBC or Sublicensing Revenue Due UBC is generated, Hana shall have                the                right and option, on consultation with the University, to make such                payments by depositing the amount thereof in local currency for the                benefit of the University in a bank or depository in such                country. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (k)   | In                further consideration for the sublicense granted hereunder, Hana                shall pay                to the University on behalf of INEX, in addition to all other amounts                due                under this Agreement, an annual maintenance fee of [***] Dollars                ($[***]                CDN) payable on or before January 2 of each year, commencing on January                2,                2007 (the “**Annual                Maintenance Fee**”)                during which this Agreement remains in full force and effect. Neither                all                nor any part of this Annual Maintenance Fee shall be refundable to                Hana                under any circumstances. |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**5.6  **
**Interest        Due to University**

| (a)   | under                this Article                5;                and |
|-----------------|------------------------------------------------------------------------|

| (b)   | under                any other Section(s) in respect of payments to be made by Hana to                the                University; |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------|

----

**5.7  **
**Sublicensing        and Royalty **
**Payments        to INEX**

| (a)   | In                consideration of the sublicense granted to Hana under this Agreement,                the                disclosure to Hana of INEX’s Confidential Information, and subject to the                provisions of this Agreement, Hana shall pay the Royalty Due INEX                and                Sublicensing Revenue Due INEX as provided herein. Hana shall also                pay to                UBC the Royalty Due UBC on Inex’s behalf. Inex shall pay to UBC the                Sublicensing Revenue Due UBC in accordance with the UBC License.                Hana and                Inex shall confirm to the other in writing the delivery of each such                payment to UBC. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)**  ** | **Sphingosomal                Vinorelbine** |
|---------------------|---------------------------------------------|

| (i)   | Milestone                Payments: |
|-----------------|------------------------------------|

| (A)   | [***]                Dollars ($[***])                upon on the date the first patient is enrolled in any clinical trial                of                Sphingosomal Vinorelbine conducted pursuant to an IND sponsored by                Hana,                of which [***]                Dollars ($[***])                shall be paid by wire transfer to INEX of immediately available funds                and                the remaining [***]                Dollars ($[***])                shall be paid by Hana issuing to INEX a number of additional shares                of                Common Stock determined by dividing [***]                Dollars ($[***])                by the FMV as of the date of such first patient                enrolment; |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (B)   | [***]                Dollars ($[***])                upon the date the first patient is enrolled in a Phase II clinical                trial                of Sphingosomal Vinorelbine conducted pursuant to an IND sponsored                by                Hana, which payment shall be made by Hana issuing to INEX a number                of                additional shares of Common Stock determined by dividing [***]                Dollars ($[***])                by the FMV as of the date of such first patient enrollment;                and |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (C)   | [***]                Dollars ($[***])                upon the approval by the FDA of an NDA relating to Sphingosomal                Vinorelbine, which payment shall be made by Hana issuing to INEX                a number                of additional shares of Common Stock determined by dividing [***]                Dollars ($[***])                by the FMV as of the date of such FDA approval; provided however,                if a                Regulatory Submission equivalent to an NDA is approved in any of                the                Designated EU States before an NDA relating to Sphingosomal Vinorelbine                is                approved by the FDA, one half the milestone due under this Section                5.7(b)(C)                will be paid by Hana to INEX immediately upon approval of that equivalent                filing and the remaining balance will be paid by Hana to INEX immediately                upon the approval of an NDA relating to Sphingosomal Vinorelbine                by the                FDA. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (D)   | For                the avoidance of doubt, each of the milestone payments described                in                subparagraphs (A) and (B) of this Section 5.7(b)(i)                above represent one-time payments to INEX, and shall be due only                upon the                first occurrence of the events described in each such subparagraph.                For                example, the milestone payment described in subparagraph (A) above                will be                due only once, following the FDA’s acceptance for review of the                Sphingosomal Vincristine NDA. No additional milestone payments to                INEX                shall be due from Hana pursuant to subparagraph (A) in connection                with any                subsequent NDA submission by Hana relating to Sphingosomal                Vincristine. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (ii)   | Royalties: |
|------------------|------------|

| (A)   | With                respect to Net Sales of Liposomal Vinorelbine in the United States,                a                royalty equal to the sum of: (i) [***]                percent ([***]%)                of Net Sales in consideration of the Patents if the Product sold                is                embraced within any Valid Claim under the Patents in the United States;                (ii) [***]                percent ([***]%)                of Net Sales in consideration of, and during any period of product                exclusivity provided by the laws of the United States of America,                including but not limited to marketing exclusivity in the form of                data                exclusivity, pediatric exclusivity, and orphan drug designation                exclusivity; and (iii) [***]                percent ([***]%)                of Net Sales in consideration of Technology; provided, however, that                the                total royalty paid shall be limited to [***]                percent ([***]%)                of cumulative Net Sales up to [***]                Dollars ($[***]),                and limited to [***]                percent ([***]%)                of cumulative Net Sales in excess of [***]Dollars                ($[***]);                and |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (B)   | With                respect to Net Sales of Sphingosomal Vinorelbine in each country                of the                Territory other than the United States, a royalty of [***]                percent ([***]%)                of Net Sales in consideration of Technology; provided, however, that                the                total royalty paid shall be limited to [***]                percent ([***]%)                of cumulative Net Sales up to [***]                Dollars                ($[***]),                and increased to [***]                percent ([***]%)                of cumulative Net Sales in excess of [***]Dollars                ($[***]). |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (iii)   | Generic                Competition: If,                during a given calendar year, there is sale                of a generic Sphingosomal Vinorelbine or sale of an approved equivalent                to                Sphingosomal Vinorelbine (collectively, “**Approved                Sphingosomal Vinorelbine Equivalents**”)                in any country in the Territory, them, for such country, the total                amount                of Royalties Due INEX for the Net Sales of Sphingosomal Vinorelbine                in                such country during such calendar year will be reduced to [***]                percent ([***]%)                of the Royalties Due INEX pursuant to Section 5.7(b)(ii)                for such calendar year, in such                country. |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (iv)   | Deductions: Notwithstanding                the schedule of royalty                payments set forth in Section 5.7(b)(ii),                Hana shall be entitled to deduct from such Sphingosomal Vinorelbine                royalty obligations owed by Hana to INEX, an amount equal to [***]                percent ([***]%)                of the research and development expenses Hana incurs in connection                with                the Development of Sphingosomal Vinorelbine (the “**Sphingosomal                Vinorelbine R&D Expenses**”);                provided however, that such deduction shall not exceed the lesser                of: |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (A)   | [***]                Dollars ($[***]);                or |
|-----------------|----------------------------------------------------------|

| (B)   | [***]                Dollars ($[***])                per patient treated in a Registrational Clinical                Trial; |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------|

| (c)**  ** | **Sphingosomal                Topotecan** |
|---------------------|-------------------------------------------|

| (i)   | Milestone                Payment:Hana                shall pay to INEX milestones payments in respect of Sphingosomal                Topotecan                as follows: |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (A)   | [***]                Dollars ($[***])                upon the date the first patient is enrolled in any clinical trial                of                Sphingosomal Topotecan conducted pursuant to an IND sponsored by                Hana,                which payment shall be made by Hana issuing to INEX a number of additional                shares of Common Stock determined by dividing [***]                Dollars ($[***])                by the FMV as of the date of such first patient                enrollment; |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (B)   | [***]                Dollars ($[***])                upon the date the first patient is enrolled in a Phase II clinical                trial                of Sphingosomal Topotecan conducted pursuant to an IND sponsored                by Hana,                which payment shall be made by Hana issuing to INEX a number of additional                shares of Common Stock determined by dividing [***]                Dollars ($[***])                by the FMV as of the date of such first patient enrollment;                and |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (C)   | [***]                Dollars ($[***])                upon the approval by the FDA of an NDA relating to Sphingosomal Topotecan,                which payment shall be made by Hana issuing to INEX a number of additional                shares of Common Stock determined by dividing [***]                Dollars ($[***])                by the FMV as the date of such FDA approval; provided however, if                a                Regulatory Submission equivalent to an NDA is approved in any of                the                Designated EU States before an NDA relating to Sphingosomal Topotecan                is                approved by the FDA, [***]                the milestone due under this Section 5.7(c)(i)(C)                will be paid by Hana to INEX immediately upon approval of that equivalent                filing and the remaining balance will be paid by Hana to INEX immediately                upon the approval of an NDA relating to Sphingosomal Topotecan by                the                FDA. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (D)   | For                the avoidance of doubt, each of the milestone payments described                in                subparagraphs (A), (B) and (C) of this Section 5.7(c)(i)                above represent one-time payments to INEX, and shall be due only                upon the                first occurrence of the events described in each such subparagraph.                For                example, the milestone payment described in subparagraph (A) above                will be                due only once, upon the date the first patient is enrolled in a clinical                trial of Sphingosomal Topotecan conducted pursuant to an IND sponsored                by                Hana. No additional milestone payments to INEX shall be due from                Hana                pursuant to subparagraph (A) in connection with any subsequent clinical                trials sponsored by Hana. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (ii)   | Royalties: |
|------------------|------------|

| (A)   | With                respect to Net Sales of Sphingosomal Topotecan in the United States,                a                royalty equal to the sum of: (i) [***]                percent ([***]%)                of Net Sales in consideration of the Patents if the Product sold                is                embraced within any Valid Claim under the Patents in the United States;                (ii) [***]                percent ([***]%)                of Net Sales in consideration of, and during any period of product                exclusivity provided by the laws of the United States of America,                including but not limited to marketing exclusivity in the form of                data                exclusivity, pediatric exclusivity, and orphan drug designation                exclusivity; and (iii) [***]                percent ([***]%)                of Net Sales in consideration of Technology; provided, however, that                the                total royalty paid shall be limited to [***]                percent ([***]%)                of cumulative Net Sales up to [***]                Dollars ($[***]),                and limited to [***]                percent ([***]%)                of cumulative Net Sales exceeding [***]                Dollars                ($[***]); |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (B)   | With                respect to Net Sales of Sphingosomal Topotecan in each country of                the                Territory other than the United States, a royalty of [***]                percent                ([***]%)                of Net Sales in consideration of Technology; provided, however, that                the                total royalty paid shall be limited to [***]                percent ([***]%)                of cumulative Net Sales up to [***]                Dollars                ($[***]),                and increased to [***]                percent ([***]%)                of cumulative Net Sales in excess of [***]                Dollars                ($[***]                ). |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (iii)   | Generic                Competition: |
|-------------------|-------------------------------------|

**Approved      Sphingosomal Topotecan Equivalents**

| (iv)   | Deductions: |
|------------------|-------------|

**Sphingosomal      Topotecan R&D Expenses**

| (A)   | [***]                Dollars ($[***]);                or |
|-----------------|----------------------------------------------------------|

----

| (B)   | [***]                Dollars ($[***])                per patient treated in a Registrational Clinical                Trial; |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------|

| (d)   | Limitation                on Payment Using Common Stock |
|-----------------|---------------------------------------------------------|

**Maximum      Issuance Amount**

| (e)   | Remuneration                Respecting Sublicensees |
|-----------------|-----------------------------------------------------|

| (i)   | In                the event Hana sublicenses its rights under Sphingosomal Vincristine                before the FDA approves the Sphingosomal Vincristine NDA or a Designated                EU State approves a Regulatory Submission that is equivalent to an                NDA,                INEX shall be entitled to receive [***]                percent                ([***]%)                of any Sublicensing Revenue Due INEX payable to Hana by such Sublicensee.                In the event Hana sublicenses its rights to Sphingosomal Vincristine                after                the FDA approves the Sphingosomal Vincristine NDA or a Designated                EU State                approves a Regulatory Submission that is equivalent to an NDA, INEX                shall                be entitled to receive [***]                percent ([***]%)                of any Sublicensing Revenue Due                INEX                payable to Hana by such                Sublicensee; |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | In                the event Hana sublicenses its rights under Sphingosomal Vinorelbine,                INEX                shall be entitled to share the Sublicensing Revenue Due                INEX                payable to Hana, if any, as                follows: |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (A)   | INEX’s                share of such Sublicensing Revenue Due                INEX                shall be [***]                percent ([***]%)                of any Sublicensing Revenue Due                INEX                payable to Hana by such Sublicensee during the period commencing                on the                Effective Date and ending on the date immediately preceding the date                the                first patient is enrolled in a Phase II clinical trial of Sphingosomal                Vinorelbine; |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (B)   | INEX’s                share of such Sublicensing Revenue Due                INEX                shall be reduced to [***]                percent ([***]%)                of                any Sublicensing Revenue Due                INEX                payable to Hana by such Sublicensee on or after the date the first                patient                is enrolled in Phase II clinical trial of Sphingosomal Vinorelbine                and                ending on the date immediately preceding the earlier to occur                of: |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (1)   | the                date the first patient is enrolled in a Phase III clinical trial                of                Sphingosomal Vinorelbine; or |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------|

| (2)   | the                acceptance of the NDA or its equivalent Regulatory Submission for                Sphingosomal Vinorelbine; and |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------|

| (C)   | INEX’s                share of such Sublicensing Revenue Due                INEX                shall be reduced to [***]                percent ([***]%)                of any Sublicensing Revenue Due                INEX                payable to Hana by such Sublicensee on or after the earlier to occur                of: |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (1)   | the                date the first patient is enrolled in a Phase III clinical trial                of                Sphingosomal Vinorelbine; or |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------|

| (2)   | the                acceptance of the NDA or its equivalent Regulatory Submission for                Sphingosomal Vinorelbine. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------|

| (iii)   | In                the event Hana sublicenses its rights under Sphingosomal Topotecan,                INEX                shall be entitled to share the Sublicensing Revenue Due                INEX payable                to Hana, if any, as follows: |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (A)   | INEX’s                share of such Sublicensing Revenue Due                INEX shall                be [***]                ([***]%)                of any Sublicensing Revenue Due                INEX payable                to Hana by such Sublicensee during the period commencing on the Effective                Date and ending on the date immediately preceding the date the first                patient is enrolled in a Phase II clinical trial of Sphingosomal                Topotecan; |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (B)   | INEX’s                share of such Sublicensing Revenue Due                INEX shall                be reduced to [***]                percent ([***]%)                of any Sublicensing Revenue Due                INEX payable                to Hana by such Sublicensee on or after the date the first patient                is                enrolled in Phase II clinical trial of Sphingosomal Topotecan and                ending                on the date immediately preceding the earlier to occur                of: |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (1)   | the                date the first patient is enrolled in a Phase III clinical trial                of                Sphingosomal Topotecan, or |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------|

| (2)   | the                acceptance of the NDA or its equivalent Regulatory Submission for                Sphingosomal Topotecan. |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------|

| (iv)   | Notwithstanding                anything to the contrary contained in this Section 5.7(e)(iii),                Hana shall have no obligation to pay to INEX its respective share                of any                such Sublicensing Revenue Due                INEX unless                and until Hana                actually                receives such Sublicensing Revenue Due                INEX from                its Sublicensee. |
|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (v)   | Where                any Sublicensing Revenue Due                INEX payable                to, collected or received by Hana or its Affiliates is in Dollars,                Hana                shall pay to INEX, INEX’s share of such Sublicensing Revenue Due                INEX within                ten                (10)                days of Hana or its Affiliate’s receipt of same. Where                any Sublicensing Revenue Due                INEX payable                to, collected or received by Hana or its Affiliates is derived from                a                country other than the United States of America, INEX’s portion of such                Sublicensing Revenue Due                INEX shall                be converted to the equivalent in Dollars on the same date that Hana                converts such Sublicensing Revenue Due                INEX to                Dollars, in which case the amount of Dollars pursuant to an actual                conversion shall be included in the Sublicensing Revenue                Due INEX                and Hana shall pay to INEX, INEX’s share of such Sublicensing                Revenue                Due INEX                within ten                (10)                days of such conversion. If at any time the Parties agree that it                is not                practical or possible for Hana to forthwith convert Sublicensing                Revenue                Due                INEX paid                in foreign currency to Dollars, or if legal restrictions prevent                the                conversion of part or all of the Sublicensing Revenue Due                INEX to                Dollars, Hana shall have the right and option, upon consultation                with                INEX, to deposit INEX’s share of such Sublicensing Revenue Due                INEX in                local currency, in an account in INEX’s sole name in a bank or depository                in the country where such Sublicensing Revenue Due                INEX is                generated. Hana                shall make such deposit within ten                (10)                days of Hana or its Affiliate’s receipt of said foreign currency. The last                date of signature of any duly executed sublicensing agreement between                Hana                and a Sublicensee shall be deemed to be the date upon which Sublicensing                Revenue                Due INEX                is                received by Hana for the purposes of determining the percentage of                Sublicensing Revenue Due                INEX payable                to INEX pursuant to Sections 5.7(b)                and 5.7(c).                Hana shall make Commercially Reasonable Efforts to inform INEX in                a timely                manner of material legislative and economic changes in such country                in                which such deposit was made so as to enable INEX to more readily                access,                convert and/or transfer from such country, INEX’s share of Sublicensing                Revenue                Due INEX                deposited in such country by Hana |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (vi)   | Notwithstanding                Section 5.7(e)(v),                if any Sublicensing Revenue                Due INEX                other than cash is payable to, collected or received by Hana or its                Affiliates,                Hana may elect to pay to INEX, INEX’s share of Sublicensing                Revenue                Due INEX                by                way of cash, common stock of Hana, common stock of another corporation                acceptable to INEX, or any combination thereof. If Hana elects to                pay INEX                using the common stock of Hana or the common stock of another corporation                acceptable to INEX, the following shall                apply: |
|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (A)   | the                last date of signature of any duly executed sublicensing agreement                between                Hana and a Sublicensee shall be deemed to be the date upon which                Sublicensing Revenue                Due INEX                is                received by Hana for the purposes of determining the percentage of                Sublicensing Revenue                Due INEX                payable to INEX pursuant to Sections 5.7(e)(i)                and 5.7(e)(ii); |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (B)   | the                value of the economic benefit of the Sublicensing Revenue Due                INEX                established by a Third                Party banker or valuator, measured in Dollars and applied to the                percentage entitlement of INEX determined pursuant to Section 5.7(e)(vi)(A),                shall be the assessed value (the “**Assessed                Value**”)                to be used in determining the number common stock of Hana or of                another corporation acceptable to INEX                payable to INEX pursuant to Section 5.7(e)(vi)(C);                and |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (C)   | Hana                will pay INEX using common stock of Hana or of another corporation                acceptable to INEX as follows: |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------|

| (1)   | the                Parties will mutually agree on the par value per share of common                stock of                Hana or of another corporation acceptable to INEX;                and |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2)   | Hana                will issue or assign to INEX as applicable, a number of common stock                of                Hana or of another corporation acceptable to INEX by dividing the                Assessed                Value by the FMV as of the date upon which Sublicensing                Revenue                Due INEX                was deemed to have been received by Hana pursuant to Section 5.7(e)(vi)(A). |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (D)   | Hana’s                payment of Sublicensing Revenue Due INEX in the form of stock pursuant                to                this Section shall                be                made within ten (10) days of Hana’s receipt of                same. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (vii)   | Hana’s                payment of Sublicensing Revenue Due INEX under this Section 5.7(e)                shall be accompanied by an accounting setting out all Sublicensing                Revenue                Due INEX payable to, collected or received by Hana or its Affiliates,                segmented according to Product, Sublicensee identified by name, and                the                last date on which each sublicensing agreement was                executed. |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (f)   | Third                Party Payments |
|-----------------|-------------------------------------|

| (i)   | If,                during the term of this Agreement: |
|-----------------|-------------------------------------------------------|

| (A)   | Hana                and INEX mutually agree that it is necessary to seek a license from                any                Third Party in the Territory in order to avoid infringement during                the                exercise of the rights herein granted;                or |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (B)   | if                as a result of any complaint alleging infringement or violation of                any                patent or other Intellectual Property Rights is made against Hana,                its                Affiliate or its Sublicensee with respect to the Manufacture, use                or sale                of a Product in the Hana Field, where such Manufacture, use or sale                is                encompassed by the Technology, and a settlement, consent judgement                or                award of Damages determined by a court of competent jurisdiction                requires                Hana to make payment of Damages to a Third Party in satisfaction                of such                complaint; or |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (C)   | if                an independent, mutually acceptable Third Party patent attorney determines                that such a license is required (in accordance with the procedure                outlined                in this Section 5.7(f)(i); |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Offset      Amount**
**Punitive      Amount**

----

| (ii)   | Notwithstanding                the provisions of Section 5.7(f),                if the license from the Third Party or the royalty or other amount                payable                to such Third Party gives rise to an indemnification obligation under                one                or more of the Definitive Agreements in favour of Hana on the part                of                INEX, then such royalty or other amount shall be paid by INEX as                Damages                in accordance therewith; provided however, that Hana agrees to use                all                reasonable efforts to avoid a finding of wilful infringement of such                Third                Party’s rights. |
|------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (g)   | Compulsory                Licenses |
|-----------------|------------------------------------|

| (i)   | avail                itself of the royalty reduction set out in Sections 5.7(b)(iv)                and 5.7(c)(iv),                if applicable; or |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | have                the benefit in such country of the same terms granted to such Third                Party                to the extent that such terms taken as a whole are more favourable                than                those of this Agreement. |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (h)   | Withholding                Taxes |
|-----------------|----------------------------------|

| (i)   | Hana                shall be deemed to be the sole payer of payments owed to INEX under                this                Agreement and shall not have the right to substitute any domestic                or                foreign Affiliate for that purpose,                and |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | in                the event that Hana takes any action, including, without limitation,                the                assignment of this Agreement, any sublicensing permitted hereby,                any                change of jurisdiction of residence or any reorganization or change                in its                business or structure so that, after such action, the withholding                tax on                the payments under this Agreement would be substantially more than                those                in effect on the Effective Date, Hana shall                either: |
|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (A)   | with                the co-operation of INEX, arrange its affairs so that the withholding                tax                consequences to INEX are not materially worse than those in effect                prior                to such action; or |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (B)   | gross                up the payments otherwise owed to INEX so that INEX receives net                of                withholding taxes the amount INEX would have received but for such                action. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | Foreign                Payments |
|-----------------|---------------------------------|

----

| (j)   | Method                of Payment |
|-----------------|----------------------------------|

| (k)   | Late                Payments |
|-----------------|------------------------------|

| (i)   | the                Prime Rate(s) during the period of late payment plus [***]                percent ([***]%)                interest compounded monthly, or |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | the                maximum rate permitted by law; |
|------------------|---------------------------------------------------|

| (l)   | Records |
|-----------------|---------|

| (m)   | Audits |
|-----------------|--------|

| (n)   | Hana                and INEX understand and recognize that there are a number of license,                sublicense and other agreements between the parties comprising the                grant                of rights by INEX to Hana. Notwithstanding that Hana’s financial                obligations to INEX may be repeated or referentially incorporated                in part                or in whole in each such agreement, the Parties agree that Hana’s                cumulative financial obligation to INEX shall comprise the                following: |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | the                Closing Payment; |
|-----------------|-------------------------------------|

----

| (ii)   | the                Closing Shares; |
|------------------|------------------------------------|

| (iii)   | Hana’s                assumption of all payment obligations of INEX                to: |
|-------------------|----------------------------------------------------------------------------------------------|

| (A)   | the                BCCA pursuant to the BCCA Agreements as defined in the License                Agreement; |
|-----------------|-------------------------------------------------------------------------------------------------------------|

| (B)   | MD                Anderson pursuant to the MD Anderson License as defined in the License                Agreement; and |
|-----------------|------------------------------------------------------------------------------------------------------------------------|

| (C)   | the                University pursuant to the UBC                License; |
|-----------------|---------------------------------------------------------------------------|

| (iv)   | Royalties                Due INEX pursuant to this Agreement;                and |
|------------------|----------------------------------------------------------------------------------|

| (v)   | Sublicensing                Revenue Due INEX pursuant to this                Agreement. |
|-----------------|-----------------------------------------------------------------------------------------|

**Article      6**
** **
**PATENTS**

**6.1  **
**IP        Committee**

**IP      Committee**

**6.2  **
**Responsibility        for Patent Prosecution and Maintenance**

| (a)   | In                respect of all patent and patent applications identified in **Schedule                “A”**,                Hana shall be responsible for:  |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | the                continued prosecution of any such pending patent applications to                the                issuance of the resulting patents; |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | the                maintenance of all such issued Patents;                and |
|------------------|-------------------------------------------------------------------------------|

| (iii)   | the                filing of additional patent applications for such Patents in any                jurisdiction world-wide, including, without limitation, any continuations,                continuations-in-part, divisionals, patents of addition, reissues,                re-examinations and extensions of or substitutes therefore, which                additional patent applications (and resulting patents) shall be                automatically included in the Patents, and the provision of this                Article                6                shall apply thereto. |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Schedule      “A”**

| (b)   | Notwithstanding                the allocation of patent prosecution and maintenance costs set forth                in                this Section 6.2,                if Hana requests IP Services from INEX in respect of any activities                which                would otherwise have been performed by Hana pursuant to Section                6.2(a)                ,                INEX shall be entitled to payment of IP Services in accordance with                the                provisions of Section 6.9                herein and the applicable provisions of the Service                Agreement |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (c)   | Hana                shall be responsible for the prosecution of the pending patent                applications included in the Patents in accordance with the                responsibilities set forth in Section 6.2(a)                and cost allocations set forth in**Schedule “A”**.                The cost allocations set out in **Schedule                “A”**shall                be subject to review and amendment by mutual agreement of the Parties                on                an annual basis on or before December 31 of each year during the                Term. In                the event that the parties cannot reach agreement on or before December                31, the matter will be resolved by arbitration in accordance with                Section                14.3. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (d)   | Hana                shall diligently pursue the prosecution of all patent applications                in                accordance with the responsibilities set forth in Section 6.2(a)                and cost allocations set forth in **Schedule                “A”**to                issuance of the resulting patents and shall not abandon, withdraw                or                discontinue prosecution of any pending patent applications included                in the                Patents without first consulting with and obtaining the prior written                consent of INEX, which consent shall not be withheld if the Parties                agree                that the issuance of a patent from such application is                unlikely. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (e)   | At                the request of INEX, Hana shall diligently pursue and prosecute additional                patent filings relating to the Patents and Technologies in any                jurisdiction worldwide in accordance with the responsibilities set                forth                in Section 6.2(a)                and cost allocations set forth in **Schedule                “A”**. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (f)   | Either                Party may request the other Party to file new patent applications,                divisionals, provisionals, non-provisionals, continuations and                continuations-in-part to ensure that Valid Claims on Patents remain                pending. If the Party having primary responsibility for patent prosecution                and maintenance decides not to meet such request, the requesting                Party                shall be entitled to, at the requesting Party’s                election: |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | refer                the matter to arbitration pursuant to 14.3;                or |
|-----------------|------------------------------------------------------------------------------------|

| (ii)   | perform                such filings and take such actions as it deems necessary and at its                sole                cost. |
|------------------|-------------------------------------------------------------------------------------------------------------------------------------|

| (iii)   | cooperate                with the requesting Party perform such filings and take such actions                as                may be required by the requesting Party if the requesting Party does                not                have standing to perform such filings and take such actions;                or |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (iv)   | grant                the requesting Party a power-of-attorney to perform such filings                and take                such actions as may be required by the requesting                Party; |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**6.3  **
**Identification        of Additional Process or Use**

**Schedule      “A”**

----

**6.4  **
**Issuance        of Patent**

**Schedule**
**A**

**6.5  **
**Improvements**

**Improvements**

| (a)   | any                and all patents and any and all patent applications that claim priority                to                such Patents (whether complete or incomplete or whether filed or                unfilled)                including, but not limited to, provisional, non-provisional, continuations                and continuations-in-part, and divisional patent applications and                registrations in any jurisdiction world-wide;                and |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | any                and all inventions arising from such patents or patent applications                whether patented or not. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------|

| (c)   | by                Hana, whether solely or jointly with any Person other than a                Sublicensee; |
|-----------------|------------------------------------------------------------------------------------------------------------|

| (d)   | by                a Sublicensee, whether solely or jointly with any Person other than                Hana;                or |
|-----------------|------------------------------------------------------------------------------------------------------------------------------|

| (e)   | jointly                by Hana and a Sublicensee; |
|-----------------|---------------------------------------------------|

**Schedule**
**A**

**6.6  **
**Consultation        and Reporting**

| (a)   | On                a timely basis, Hana will consult with or instruct its patent agent(s)                and/or patent counsel(s) to consult with INEX, and INEX will consult                with                or instruct its patent agent(s) and/or patent counsel(s) to consult                with                Hana, regarding the claims and any proposed amendments thereto of: |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | any                Patents pending and issued; and |
|-----------------|----------------------------------------------------|

| (ii)   | any                additional patent applications to be included in the                Patents; |
|------------------|-------------------------------------------------------------------------------------------------|

| (b)   | On                a timely basis, Hana shall provide INEX with copies of the material                correspondence and documents which Hana sends or receives in connection                with the application, prosecution and maintenance of Patents, and                INEX                shall provide Hana with copies of the material correspondence and                documents which INEX sends or receives in connection with the application,                prosecution and maintenance of                Patents |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (c)   | Provided                a Party has provided timely notice and copies of material correspondence                to the other Party of any matter requiring any action relating to                any                application, prosecution or maintenance of the Patents, the Party                providing timely notice shall not be found to be in breach of its                obligations under this Article                6                if                the other Party, its patent agent(s) and/or patent counsel(s) fail                to                consult with or provide written instructions to the Party providing                timely                notice, at least five (5) Business Days prior to any deadline including                an                extendible deadline, in respect of any action required for the                application, prosecution or maintenance of the Patents.  |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (d)   | Hana                acknowledges and agrees that any report provided by Hana to INEX                in                accordance with this Article                6                may be used by INEX in INEX’s preparation of reports to the                University. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**6.7          **
**Reports**

| **6.8  ** | **                  Abandonment, Withdrawal or                Discontinuance** |
|---------------------|------------------------------------------------------------------------------------------|

| (a)   | Notwithstanding                each Party’s obligation under Section 6.2,                should either Party decide to: |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------|

| (i)   | discontinue                pursuing one or more patent applications, patent protection or patent                maintenance for one or more patents in relation to the Patents or                any                continuation, continuation in-part, divisional, reissue, re-examination                or                extension thereof for any reason; |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | not                pursue patent protection in relation to the Patents in any specific                jurisdiction for any reason; or |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------|

| (iii)   | discontinue                or not pursue patent protection in relation to any further process,                use or                Product arising out of the Patents in any jurisdiction for any                reason; |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Abandoning      Party**
**Non-Abandoning      Party**
**Notice      of Abandonment**

| (b)   | The                Notice of Abandonment to be given by the Abandoning Party pursuant                to                Section 6.8(a)                shall clearly identify the patent applications, patent protection,                and/or                patent maintenance for the Patents to be abandoned.  |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | Each                of the Parties agrees that notwithstanding any provision to the contrary                in this Agreement, effective upon the date of the Non-Abandoning                Party’s                receipt of the Notice of Abandonment, the Abandoning Party shall                lose all                right to any and all uses of:  |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (i)   | the                patent(s) and patent application(s) to which such Party’s Notice of                Abandonment applies; and |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | any                continuation, continuation-in-part, divisional, reissue, re-examination,                or extension of or to the                foregoing; |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Discontinued      Patent**

| (d)   | Subject                to Hana having obtained the University’s prior written consent to the                abandonment of a Patent if Hana gives Notice of Abandonment to INEX                pursuant to Sections 6.8(a)                and 6.8(b),                this sublicense shall be terminated with respect solely to the                Discontinued Patent, and Hana shall forfeit the right to any and                all uses                of the Discontinued Patent and technology claimed in such Discontinued                Patent. **Schedule**“**A**”** **will                be deemed to be amended to exclude such Discontinued Patent and technology                claimed in such Discontinued Patent from the grant of sublicense                contained                herein. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (e)   | If                Hana has given Notice of Abandonment to INEX pursuant to Sections                6.8(a)                and 6.8(b),                and INEX wishes to continue to pursue any patent applications, patent                protection and/or patent maintenance in relation to Hana’s Discontinued                Patent:  |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | within                ten (10) Business Days of INEX’s receipt of Hana’s Notice of Abandonment,                INEX shall provide Hana with written notice of INEX’s intention to pursue                any patent applications, patent protection and/or patent maintenance                in                relation to Hana’s Discontinued                Patent; |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | Hana                shall relinquish patent prosecution and maintenance of Hana’s Discontinued                Patent and INEX shall assume patent prosecution and maintenance of                same,                at INEX’s sole cost and expense;                and |
|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (iii)   | notwithstanding                the Non-Competition Terms, INEX                shall have the exclusive right to use Hana’s Discontinued Patent and                technology claimed in Hana’s Discontinued Patent, in the Hana Field. |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (f)   | Subject                to INEX having obtained the University’s prior written consent to the                abandonment of a Patent, If INEX gives Notice of Abandonment to Hana                pursuant to Sections 6.8(a)                and 6.8(b),                INEX shall forfeit the right to any and all uses of the Discontinued                Patent and technology claimed in any Discontinued Patent, notwithstanding                that INEX may remain the nominal owner of such Discontinued                Patent. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (g)   | If                INEX has given Notice of Abandonment to Hana pursuant to Sections                6.8(a)                and 6.8(b)                and Hana wishes to continue to pursue any patent applications, patent                protection and/or patent maintenance in relation to INEX’s Discontinued                Patent: |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | within                ten (10) Business Days of Hana’s receipt of INEX’s Notice of Abandonment,                Hana shall provide INEX with written notice of Hana’s intention to pursue                any patent applications, patent protection and/or patent maintenance                in                relation to INEX’s Discontinued Patent, at Hana’s sole cost and expense;                and |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | notwithstanding                the Non-Competition Agreement, Hana                shall have the exclusive right to use INEX’s Discontinued Patent and the                technology claimed in INEX’s Discontinued Patent, outside the Hana                Field. |
|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (h)   | INEX                may request Hana to perform Hana’s responsibilities set forth in Sections                6.2(a)                in                respect of a particular patent or patent application. If Hana is                unwilling                or unable to perform its responsibility in a timely manner, INEX                may, with                three (3) days prior written notice, perform the particular activity(ies)                requested in respect of such patent or patent application. Hana shall                pay                all reasonable costs and out-of-pocket expenses actually incurred                by INEX                to perform the particular activity(ies) requested, within thirty                (30) days                of Hana’s receipt of INEX’s invoice for such costs and out-of-pocket                expenses. For the purposes of this Section 6.8(h),                reasonable costs shall                be calculated using the FTE Rate set forth in the Service Agreement,                and                notwithstanding any termination of the Service Agreement.  |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**6.9          **
**Costs        of Patent Application, Prosecution and Maintenance**

| (a)   | Commencing                from the date that an Abandoning Party has lost all entitlement to                a                Discontinued Patent, such Abandoning Party shall not be required                to share                in any costs (and fees for IP Services if INEX is the Abandoning                Party)                associated with the application, prosecution, and/or maintenance                of any                Patents in the Discontinued Patent. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | Subject                to Section 6.8                and notwithstanding any termination of the Service Agreement, for                as long                as INEX continues to perform at Hana’s request, the activities required                for intellectual property portfolio management and all associated                activities including, without limitation, patent application, filing,                prosecution and maintenance, and payment of all government and legal                fees                required to apply for, prosecute and maintain the Patents described                in                Section 6.2(a)                (the “**IP                Services**”),                Hana, its successors, assigns or any Person(s) who acquires any interest                in any of the Technology will jointly and severally be responsible                for                paying INEX:  |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | [***]                percent                ([***]%)                of all reasonable out-of-pocket costs, including, without limitation,                filing fees, fees for external counsel(s), patent agent(s), contractors,                travel, and lodging expenses incurred by INEX to provide IP Services;                and |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | [***]                percent                ([***]%)                of the personnel costs incurred by INEX, calculated at INEX’s FTE Rate,                pro rated to reflect the actual time employees, contractors or consultants                of INEX spend providing IP Services; provided however, that on each                anniversary of the Effective Date, the FTE Rate shall be raised by                a                percentage equal to the percentage increase in the Consumer Price                Index                (All Items) for the province of British Columbia for the twelve (12)                month                period ending with December of the calendar year immediately preceding                such anniversary date; and |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (iii)   | [***]                percent                ([***]%)                of all out-of-pocket costs and [***]                percent                ([***]%)                of all personnel costs incurred by INEX to provide IP Services in                respect                of any Discontinued Patent which Hana has elected to continue pursuing                patent protection, pursuant to Section 6.8(g). |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | INEX                will invoice Hana monthly for all costs set forth in Section 6.9(b),                plus all applicable taxes thereon, on or before the 30th                day after the end of the month in which the IP Services were rendered                and/or expenses incurred; provided however, that any out-of-pocket                costs                incurred which are not captured in any invoice may be captured in                subsequent invoices. Hana will pay all amounts due and payable hereunder                in full in US Dollars to INEX within thirty (30) days of the date                of each                such invoice, by cheque or wire transfer to the account specified                by                INEX. |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (d)   | Notwithstanding                Section 6.9(c),                during the Term, INEX shall not combine Hana’s payment obligations for IP                Services under the Service Agreement together with Hana’s payment                obligations under this Section to recover from Hana, its successors,                assigns or any Person(s) who acquires any interest in any of the                Technology, more than the total monthly costs set forth in Section                6.9(b)                in                any given month. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**6.10          **
**Late        Payments**

| (a)   | the                Prime Rate(s) during the period of late payment plus [***]                percent ([***]%)                interest compounded monthly; or |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | the                maximum rate permitted by law; |
|-----------------|---------------------------------------------------|

**6.11         **
**Co-operation**

| (a)   | making                available to the other Party or such other Party’s Representatives whom                the other Party in its reasonable judgment deems necessary in order                to                assist it in obtaining patent protection of the Patents;                and |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | executing                and causing its Representatives to execute all legal documents reasonably                necessary to support the assignment, filing, prosecution and maintenance                of said Patents. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**6.12  **
**Injunctive        Relief**

**Article      7**
** **
**DISCLAIMERS,      REPRESENTATIONS AND WARRANTIES**

**7.1**
**Disclaimer**

| (a)   | ,The                University makes no representations, conditions, or warranties, either                express or implied, with respect to the Technology or the Product.                Without                limiting the generality of the foregoing, the University specifically                disclaims any implied warranty, condition, or representation that                the                Technology or the Product: |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | shall                correspond with a particular                description; |
|-----------------|-------------------------------------------------------------------------------|

| (ii)   | are                of merchantable quality; |
|------------------|---------------------------------------------|

| (iii)   | are                fit for a particular purpose; or |
|-------------------|-----------------------------------------------------|

| (iv)   | are                durable for a reasonable period of                time. |
|------------------|----------------------------------------------------------------------------|

| (b)   | The                University shall not be liable for any Damages, or any other loss                whether                direct, indirect, consequential, incidental, or special which Hana                or its                Affiliates suffer arising from any defect, error, fault, or failure                to                perform with respect to the Technology or Product, even if the University                has been advised of the possibility of such defect, error, fault,                or                failure. Hana and its Affiliates acknowledge that they have been                advised                by the University and INEX to undertake their own due diligence with                respect to the Technology and                Product. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (c)   | EXCEPT                FOR THE EXPRESS WARRANTIES AND REPRESENTATIONS CONTAINED IN THIS                AGREEMENT, NEITHER INEX NOR HANA MAKES, AND EACH HEREBY EXPRESSLY                DISCLAIMS, ANY WARRANTIES OR REPRESENTATIONS, EITHER EXPRESS OR IMPLIED,                WHETHER IN FACT OR IN LAW, INCLUDING WITHOUT LIMITATION IMPLIED WARRANTIES                OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR                NON-INFRINGEMENT. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**7.2**
**International      Sale of Goods Act Not Applicable**

**7.3**
**No      Implied Warranties**

| (a)   | a                warranty or representation by the University or INEX as to title                to the                Technology or that any Product or anything made, used, sold or otherwise                disposed of under the sublicense granted in this Agreement will not                infringe the patents, copyrights, trade-marks, industrial design                or other                intellectual property rights of any third parties, including any                patents,                copyrights, trade-marks, industrial design or other intellectual                property                rights owned, in whole or in part, by UBC, or licensed directly or                indirectly by UBC to any Person; |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | a                warranty or representation by UBC that Hana or its Affiliates or                any of                their Sublicensees have, or will have the freedom to operate or practice                the Technology; or |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | an                obligation by the University to bring or prosecute or defend actions                or                suits against any Person for infringement of patents, copyrights,                trade-marks, industrial designs or other intellectual property or                contractual rights; or |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (d)   | the                conferring by the University of the right to use in advertising or                publicity the name of INEX or the University or UBC                Trade-marks. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**7.4           **
**Limited        Warranty**

**Schedule**
**A**

**7.5  **
**Conduct        of Infringement Proceedings**

| (a)   | an                alleged infringement by a Third Party of the Technology or of any                right                with respect to the Technology by the manufacture, sale, services                or use                of products derived from the Technology in the Hana Field; or |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (b)   | any                complaint by Hana alleging any infringement by a Third Party with                respect                to the Technology or to any right with respect to the Technology                by the                manufacture, sale, services or use of product or services in the                Hana                Field; |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | Hana                shall have the first right, in its sole discretion, to prosecute                or defend                such litigation; |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------|

| (d)   | if                Hana does not take steps to prosecute or defend such litigation within                thirty (30) days after receipt of notice thereof, INEX may take such                legally permissible action as it deems necessary or appropriate to                prosecute or defend such litigation, but shall not be obligated to                do                so; |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (e)   | the                Party prosecuting or defending such litigation (in this Section,                the                “**Litigating                Party**”)                shall have the right to control such litigation and shall bear all                legal                expenses (including court costs and legal fees), but it shall have                no                right to settle any dispute in any manner which will restrict the                claims                in or admit any invalidity of any Patent(s) or significantly adversely                affect the rights of the other Party to this Agreement (the “**Non-litigating                Party**”).                By way of example and not by way of limitation, there shall be no                right of                the Litigating Party to stipulate or admit to the invalidity or                unenforceability of any Patent(s). Before any action is taken by                the                Litigating Party which could abridge the rights of the Non-litigating                Party hereunder, the Parties agree to, in good faith, consult with                a goal                of adopting a mutually satisfactory                position; |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (f)   | the                Parties further acknowledge that solely to the extent that any final                disposition of the litigation that will restrict the claims in or                admit                any invalidity of any Patent(s) or significantly adversely affect                the                University’s rights, any such disposition of the litigation requires the                full consultation with and approval by the University under the UBC                License; |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (g)   | the                Non-litigating Party agrees to co-operate reasonably in any such                litigation to the extent of executing all necessary documents, supplying                essential documentary evidence and making essential witnesses then                in its                employment available and to vest in the Litigating Party the right                to                institute any such suits, so long as all the direct or indirect costs                and                expenses of bringing and conducting any such litigation or settlement                shall be borne by the Litigating Party,                provided that INEX and Hana shall recover their respective actual                out-of-pocket expenses, or equitable proportions thereof, associated                with                any litigation or settlement thereof from any recovery made by any                Party.                Any excess amount remaining after satisfaction of the Parties’ recovery of                their respective actual out-of-pocket expenses, or equitable proportions                thereof, associated with any litigation or settlement thereof from                any                recovery made by any Party (the “**Excess                Amount**”)                shall be shared between                Hana and INEX                on                the same basis as set forth in Sections 5.7(b)(ii)                and 5.7(c)(ii)                with respect to Royalties from Net Sales of Product in the applicable                jurisdiction;                provided however, that any Excess Amount in the form of punitive                damages                shall be shared between Hana and INEX in proportion to each Party’s                contribution to litigation expenses. In the event a settlement or                consent                judgement does not distinguish between the forms of damages payable                by the                Third Party, and Hana and INEX cannot agree on what portion, if any,                of                the Excess Amount constitutes punitive damages, the Parties will                refer the                matter to arbitration in accordance with 14.3; |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (h)   | the                Litigating Party shall keep the Non-litigating Party and the University                fully informed of the actions and positions taken or proposed to                be taken                by the Litigating Party (on behalf of itself or a sublicensee) and                actions                and positions taken by all other parties to such                litigation; |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | in                the event that INEX prosecutes or defends such litigation, Hana may                elect                to participate formally in the litigation to the extent that the                court may                permit, but any additional expenses generated by such formal participation                shall be paid by Hana (subject to the possibility of recovery of                some or                all of such additional expenses as described in Section 7.5(g)                or                from such other parties to the litigation); |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (j)   | in                the event that Hana prosecutes or defends such litigation, Hana                acknowledges that the University may elect to participate formally                in the                litigation to the extent that the court may permit, but any additional                expenses generated by such formal participation shall be paid by                the                University (subject to the possibility of recovery of some or all                of such                additional expenses from such other parties to the litigation);                and |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**7.6  **
**Breach        of Confidence Proceedings**

**7.7  **
**Defense        of Infringement Proceedings**

| (a)   | If                any complaint alleging infringement or violation of any patent or                other                proprietary rights is made against Hana or its Sublicensee, with                respect                to the Manufacture, use or sale of a Product, the following procedure                shall be adopted: |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | Hana                shall promptly notify INEX upon receipt of any such complaint and                shall                keep INEX fully informed of the actions and positions taken by the                complainant and taken or proposed to be taken by Hana (on behalf                of itself                or a Sublicensee); |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | if                such complaint gives rise to an indemnification obligation under                the                Definitive agreements in favor of Hana (or its Sublicensee) on the                part of                INEX, then INEX shall defend such suit and                all costs and expenses incurred by Hana (or its Sublicensee) in                investigating, resisting, litigating and settling such a complaint,                including the payment of any award of damages and/or costs to any                Third                Party, shall be paid by INEX; |
|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (iii)   | if                such complaint does not give rise to an indemnification obligation                under                the Definitive Agreements in favor of Hana on the part of INEX, then                Hana                shall have the right but not the obligation to defend such suit and                all                costs and expenses incurred by Hana (or any Sublicensee) in investigating,                resisting, litigating and settling such a complaint, including the                payment                of any award of Damages and/or costs to any Third Party, shall be                paid by                Hana (or any Sublicensee, as the case may be);                and |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (iv)   | in                any event, INEX and Hana shall assist one another and cooperate in                any                such litigation at each Party’s own                expense. |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | If                any complaint alleging infringement or violation of any patent or                other                proprietary rights is made against INEX, its Affiliate or sublicensee                with                respect to the Manufacture, use or sale of a Product, the following                procedure shall apply: |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | INEX                shall promptly notify Hana in writing                upon receipt of any such complaint setting out full details thereof                and                shall keep Hana fully informed of the actions and positions taken                by the                complainant and taken or proposed to be taken by INEX(on                behalf of itself, its Affiliate or a sublicensee); |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | if                such a complaint gives rise to an indemnification obligation under                the                Definitive Agreements in favor of INEX (or                its Affiliate or sublicensee) on                the part of Hana, then Hana shall defend such suit and all costs                and                expenses incurred by INEX (or its Affiliate or sublicensee) in                investigating, resisting, litigating and settling such a complaint,                including the payment of any award of Damages and/or costs to any                Third                Party, shall be paid by Hana; |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (iii)   | If                such complaint does not give rise to an indemnification obligation                under                the Definitive Agreements in favor of INEX (or its Affiliate or                sublicensee) on the part of Hana, then INEX shall have the right                but not                the obligation to defend such suit and all costs and expenses incurred                by                INEX (or its Affiliate or sublicensee) in investigating, resisting,                litigating and setline such a complaint, including the payment of                any                award of Damages and/or costs to any Third Party, shall be paid by                INEX; |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (iv)   | In                any event, INEX and Hana shall assist one another and cooperate in                any                such litigation at each Party’s own                expense. |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | With                regard to costs and expenses incurred by Hana (or any Sublicensee)                under                Sections 7.7(a)(iii)                or                7.7(b)(ii)                in                investigating, resisting, litigating and settling such a complaint,                including the payment of any award of Damages and/or costs to any                Third                Party (the “**Offset                Amount**”),                but not including any punitive award (the “**Punitive                Amount**”),                Hana (or any Sublicensee) shall be entitled to offset or credit                [***]                percent ([***]%)                of the Offset Amount against future payments otherwise due INEX as                set                forth in Section 5.7(f)(i).                With regard to any Punitive Amount (eg. willful infringement), the                same is                not included in the Offset Amount and is not to be offset or credited                against future payments due INEX. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (d)   | In                the event a complaint is made under either of Sections 7.7(a)                or                7.7(b),                no                settlement or consent judgment or other voluntary final disposition                may be                entered into without the consent of the other Party or the University                if                such settlement would require the other Party or the University to                be                subject to an injunction or to make a monetary payment or would restrict                the claims in or admit any invalidity of any Licensed Patents or                significantly adversely affect the rights of the other Party or the                University. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (e)   | If                as a result of a proceeding alleging infringement or violation of                any                patent or other proprietary rights is made against Hana or its Sublicensee                with respect to the Manufacture, use or sale of a Product, Hana agrees                with a complainant to not pursue a Product which would otherwise                generate                a Royalty, the Parties agree that, in the event the University desires                to                acquire a co-exclusive right with Hana to the patent(s) for use of                the                Product for a specific field in the Hana Field, Hana agrees to enter                negotiations with the University for such a co-exclusive                    right. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**7.8  **
**Co-operation        with Other Licensees**

| (a)   | fields                outside the Hana Field that may reasonably affect Hana’s use of the                Technology in the Hana Field or the Manufacture, use or sale of Product                by                Hana; or |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | the                Hana Field that may reasonably affect INEX or one or more of INEX’s                sublicensee’s use of the Technology outside the Hana Field or the                manufacture, use or sale of products outside the Hana Field by INEX                or one                or more other such sublicensee(s); |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**7.9  **
**Hana        Representations and Warranties**

| (a)   | Hana                is a corporation duly organised, existing, and in good standing under                the                laws of Delaware and has the power, authority, and capacity to enter                into                this Agreement and to carry out the transactions contemplated by                this                Agreement, all of which have been duly and validly authorised by                all                requisite corporate proceedings; |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | the                execution, delivery and performance by Hana of this Agreement do                not                contravene or constitute a default under any provision of applicable                law                or its articles or by-laws (or equivalent documents) or of any judgment,                injunction, order, decree or other instrument binding upon                Hana; |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | all                licenses, consents, authorizations and approvals, if any, required                for the                execution, delivery and performance by Hana of this Agreement have                been                obtained and are in full force and effect and all conditions thereof                have                been complied with, and no other action by or with respect to, or                filing                with, any governmental authority or any other Person is required                in                connection with the execution, delivery and performance by Hana of                this                Agreement; |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (d)   | this                Agreement constitutes a valid and binding agreement of Hana, enforceable                against Hana in accordance with its terms, except as such enforceability                may be limited by bankruptcy, insolvency, moratorium or creditors’ rights                generally; |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (e)   | the                execution, delivery and performance by Hana of this Agreement do                not and                will not conflict with or result in a material breach of any of the                terms                and provisions of any Third Party agreement of Hana entered into                as of the                Effective Date; |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (f)   | Hana                is not aware of any impediment, including without limitation any                Third                Party agreement of Hana, which would prevent Hana from performing                its                obligations under this Agreement; |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (g)   | Hana                will not enter into any Third Party agreement after the Effective                Date                which, in any way, will prevent                Hana from performing                all of its                obligations hereunder; |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (h)   | the                authorized capital stock                of                Hana consists                of 100,000,000 shares of Common Stock, of which 22,658,202 shares                are                issued and outstanding as of the date of this Agreement, and 10,000,000                shares of preferred stock, par value $0.001 per share, none of which                is                issued and outstanding. All of such issued and outstanding shares                of                Common Stock                have been validly issued and are outstanding as fully paid and                non-assessable; |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | the                issuance of the Common Stock has been duly authorized by all necessary                action on the part of Hana and no further action is required by Hana                or                its board of directors or shareholders to complete the issuance of                the                Common Stock; |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (j)   | the                Common Stock, when issued, will be duly and validly issued, fully                paid and                non-assessable and will be free and clear of all liens, charges,                encumbrances and any rights of others. Hana has reserved from its                duly                authorized capital stock a number of shares sufficient to meet its                obligations to issue the Common Stock hereunder;                and |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (k)   | no                consent, approval, authorization or other order of any governmental                authority is required to be obtained by Hana in connection with the                authorization and issuance of Common Stock, except for such registrations,                filings or notices as have been made or as may be required to be                made                pursuant to U.S. or Canadian securities                laws. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**7.10  **
**INEX        Representations and Warranties**

| (a)   | INEX                is a corporation duly organised, existing, and in good standing under                the                laws of British Columbia and has the power, authority, and capacity                to                enter into this Agreement and to carry out the transactions contemplated                by this Agreement, all of which have been duly and validly authorised                by                all requisite corporate                proceedings; |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | the                execution, delivery and performance by INEX of this Agreement do                not                contravene or constitute a default under any provision of applicable                law                or its articles or by-laws (or equivalent documents) or of any judgment,                injunction, order, decree or other instrument binding upon                INEX; |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | all                licenses, consents, authorizations and approvals, if any, required                for the                execution, delivery and performance by INEX                of                this Agreement have been obtained and are in full force and effect                and all                conditions thereof have been complied with, and no other action by                or with                respect to, or filing with, any governmental authority or any other                Person                is required in connection with the execution, delivery and performance                by                INEX                of                this Agreement; |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (d)   | this                Agreement constitutes a valid and binding agreement of INEX, enforceable                against INEX in accordance with its terms, except as such enforceability                may be limited by bankruptcy, insolvency, moratorium or creditors’ rights                generally; |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (e)   | the                execution, delivery and performance by INEX of this Agreement do                not and                will not conflict with or result in a material breach of any of the                terms                and provisions of any Third Party agreement of INEX entered into                as of the                Effective Date; |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (f)   | INEX                is not aware of any impediment, including without limitation any                Third                Party agreement of INEX, which would prevent INEX from performing                its                obligations under this Agreement; |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (g)   | INEX                will not enter into any Third Party agreement after the Effective                Date                which, in any way, will prevent                INEX from performing                all of its                obligations                hereunder; |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (h)   | except                for the Intellectual Property Rights described in this Agreement,                INEX                neither owns nor controls any Intellectual Property Rights that would                be                required by Hana in order to make,                have made, use, sell, offer for sale, import, and have imported Products                in the Hana Field within the                Territory; |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | to                the actual knowledge of INEX,                without independent investigation or inquiry,                the rights to the Technology granted by INEX to Hana pursuant to                this                Agreement are all of the Intellectual Property Rights necessary for                Hana                to make, have made, use, sell, offer for sale, import, and have imported                Products in the Hana Field within the Territory, without any infringement                of or conflict with the Intellectual                Property Rights of Third Parties. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Article      8**
** **
**INDEMNITY      AND LIMITATION OF LIABILITY**

**8.1  **
**Rights        of the University**

| (a)   | Hana                hereby indemnifies, holds harmless and defends the University, its                Board                of Governors, officers, employees, faculty, students, invitees and                agents                (collectively, in this Article                8,                the “**University                Indemnified Parties**”)                against any and all claims (including all legal fees and disbursements                incurred in association therewith) arising out of the exercise of                any                rights under this Agreement, the UBC License or the UBC Consent,                including, without limiting the generality of the foregoing, against                any                damages or losses, consequential or otherwise, arising from or out                of the                use of the Technology or Product sublicensed under this Agreement                by Hana,                its Affiliates or its Sublicensees, or their customers or end-users                howsoever the same may arise, or any injury or death to any Person                or                damage to any property caused by any Product, whether claimed by                reason of                breach of warranty, negligence, product defect or otherwise, and                regardless of the form in which any such claim is made.  |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | Hana                agrees and acknowledges that subject to Section 8.1(c): |
|-----------------|-----------------------------------------------------------------------------|

| (i)   | the                University’s total liability, whether under the express or implied terms                of this Agreement, the UBC License or the UBC Consent, in tort (including                negligence), or at common law, for any loss or damage suffered by                Hana or                its Affiliates, whether direct, indirect, special, or any other similar                or                like damage, to the extent that such losses or damage may arise or                does                arise from any breaches of the UBC License, this Agreement or the                UBC                Consent, by the University Indemnified Parties, shall be limited                to the                sum of $[***]                CDN;                and |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | INEX’s                total liability, whether under the express or implied terms of this                Agreement, in tort (including negligence), or at common law, for                any loss                or damage suffered by Hana, whether direct, indirect, special, or                any                other similar or like damage, to the extent that such losses or damage                may                arise or does arise from any breaches of the UBC License by the University                Indemnified Parties, shall be limited to the sum of $[***]                CDN. |
|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | In                no event shall the University be liable for consequential or incidental                damages arising from any breach or breaches of the UBC License, this                Agreement or the UBC Consent. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**8.2  **
**Indemnification        by **
**INEX**
** **

**Hana      Indemnitees**

| (a)   | the                breach of any representation or warranty made by INEX                herein; |
|-----------------|-------------------------------------------------------------------------------------------------|

| (b)   | the                default by INEX in the performance or observance of any of its obligations                to be performed or observed hereunder;                and |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | the                breach by INEX of any Regulatory Requirements, regulations and guidelines                in connection with any Technology. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------|

| (d)   | the                breach of any representation or warranty made by Hana                herein; |
|-----------------|-------------------------------------------------------------------------------------------------|

| (e)   | the                default by Hana in the performance or observance of any of its obligations                to be performed or observed                hereunder; |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (f)   | the                breach by Hana or its Sublicensees, of any Regulatory Requirements,                regulations and guidelines in connection with any Product;                and |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (g)   | any                injury or death to any Person or damage to any property caused by                any                Product provided by Hana or its Sublicensees, whether claimed by                reason of                breach of warranty, negligence, product defect or otherwise, and                regardless of the form in which any such claim is                made. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**8.3  **
**Indemnification        by**
** **
**Hana**
** **

**INEX      Indemnitees**

| (a)   | the                breach of any representation or warranty made by Hana                herein; |
|-----------------|-------------------------------------------------------------------------------------------------|

| (b)   | the                default by Hana in the performance or observance of any of its obligations                to be performed or observed                hereunder; |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | the                breach by Hana, or its Sublicensees, of any Regulatory Requirements,                regulations and guidelines in connection with any Product; |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (d)   | any                complaint alleging infringement or violation of any patent or other                proprietary rights is made against INEX or its Affiliates with respect                to                Hana’s Manufacture, use or sale of a Product; and |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (e)   | any                injury or death to any Person or damage to any property caused by                any                Product provided by Hana or its Sublicensees, whether claimed by                reason of                breach of warranty, negligence, product defect or otherwise, and                regardless of the form in which any such claim is                made. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (f)   | the                breach of any representation or warranty made by INEX                herein; |
|-----------------|-------------------------------------------------------------------------------------------------|

| (g)   | the                default by INEX in the performance or observance of any of its obligations                to be performed or observed hereunder;                and |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (h)   | the                breach by INEX of any Regulatory Requirements, regulations and guidelines                in connection with any Technology. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------|

**8.4  **
**Notice        of Claims**

**Indemnitee**
**Indemnitor**

| (a)   | the                Indemnitor is granted, subject to the provisions of this Section                8.4                and the relevant provisions of Sections 7.5,                7.7                and 7.8,                full authority and control over the defense, including settlement,                against                such claim or law suit or other action,                and |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | the                Indemnitee cooperates fully with the Indemnitor and its agents in                defense                of the claims or law suit or other                action. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**8.5  **
**Consequential        Losses**

----

**8.6  **
**Action        Between the Parties**

**Article      9**
** **
**PUBLICATION      AND CONFIDENTIALITY**

**9.1**
**Treatment      of Confidential Information**

| (a)   | The                Discloser’s Confidential Information shall be developed, received, and                used by the Recipient solely in furtherance of the purposes set forth                in                this Agreement subject to the terms and conditions set forth in this                Article                9. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | The                Recipient shall keep and use all of the Discloser’s Confidential                Information in confidence and will not, without the Discloser’s prior                written consent, disclose any of the Discloser’s Confidential Information                to any person or entity, except those of the Recipient’s officers,                employees, consultants, professional advisors, agents and assigns                who                require said Confidential Information in performing their obligations                under this Agreement. The Recipient covenants and agrees that it                will                initiate and maintain an appropriate internal program limiting the                internal distribution of the Discloser’s Confidential                Information. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | The                Recipient shall not use, either directly or indirectly, any of the                Discloser’s Confidential Information for any purpose other than as                contemplated herein without the Discloser’s prior written                consent. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (d)   | If                the Recipient is required by judicial or administrative process to                disclose any or all of the Discloser’s Confidential Information, the                Recipient shall promptly notify the Discloser and, when available,                allow                the Discloser reasonable time to oppose such process before disclosing                any                Confidential Information as provided in Section 9.4(b). |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (e)   | Notwithstanding                any termination or expiration of this Agreement, the obligations                created                in this Article                9                shall survive and be binding upon the Recipient, its successors and                assigns. |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**9.2  **
**Publications**

| (a)   | INEX                provides to Hana within five (5) days after receipt from the University,                copies of any proposed publication or presentation provided to INEX                by the                University; and |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | Hana                has not, within twenty-one (21) days after receipt of said copies,                objected to INEX in writing to such proposed presentation or proposed                publication in accordance with Section 9.3                of                this Agreement. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**9.3  **
**Objections        to Publication**

| (a)   | Either                Party may object to the University’s proposed presentation or proposed                publication on the grounds that: |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | it                contains Confidential Information that was disclosed to the University                by                Hana or INEX; or  |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | it                discloses patentable subject matter which needs protection. |
|------------------|-------------------------------------------------------------------------------|

| (b)   | If                either Party makes an objection under Section 9.3(a)(i),                the Party so objecting shall specify the portions of the presentation                or                publication considered objectionable (the “**Objectionable                Material**”).                INEX shall forward all objections to the University within four (4)                days                of issuing or receiving an objection. Upon receipt of notification                from                Hana that any proposed publication or disclosure contains Objectionable                Material, the University and INEX shall work together to revise the                proposed publication or presentation to remove or alter the Objectionable                Material in a manner acceptable to Hana, in which case Hana shall                withdraw                its objection. INEX shall co-operate in all reasonable respects in                making                revisions to any proposed disclosures if considered by Hana to contain                Objectionable Material. Hana acknowledges that the University shall                not be                restricted from publishing or presenting the proposed disclosure                as long                as the Objectionable Material has been removed. In respect of any                disclosures by the University pursuant to Section 9.7 of the UBC                License,                upon Hana’s request, INEX shall request that Hana’s Confidential                Information shall be deleted therefrom prior to disclosure by the                University.  |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | If                Hana makes an objection under Section 9.3(a)(i),                thereafter Hana and/or INEX may file a patent application and the                Parties                acknowledge that the University is obligated under the UBC License                to                ensure that its researchers refrain from making such publication                or                presentation until one or more patent applications have been filed                with                one or more patent offices directed to such patentable subject matter,                or                until three (3) months have elapsed from date of receipt of the written                objection by the University, whichever is sooner, after which the                University and its researchers may proceed with said presentation                or                publication. For greater certainty, a provisional patent application                shall                be considered to be a patent application in the United States of                America                for the purposes of this Agreement. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**9.4  **
**Permitted        Disclosures**

| (a)   | Each                Party requires of the other, and each Party agrees insofar as it                may be                permitted to do so at law, that this Agreement, and each part of                it, is                confidential and shall not be disclosed to Third Parties. Notwithstanding                the foregoing, Hana hereby consents to the disclosure by INEX of                the terms                and conditions of this Agreement to the University, solely for the                purpose                of obtaining the consent of the University in accordance with the                UBC                License, and INEX shall use reasonable efforts to ensure that the                University is informed of the confidential nature of this Agreement,                and                each part of it, insofar as it may be permitted to do so at law,                shall not                be disclosed by the University to Third Parties, as Hana claims that                such                disclosure would or could reveal commercial, scientific or technical                Information and would significantly harm Hana’s competitive position                and/or interfere with Hana’s negotiations with prospective Sublicensees.                Notwithstanding anything contained in this Section, the Parties hereto                acknowledge and agree that the University may identify the title                of this                Agreement, the Parties to this Agreement, the inventors of the Technology                and the term of this Agreement. |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (b)   | Notwithstanding                Section 9.1(b),                either Party may disclose:  |
|-----------------|------------------------------------------------------------------------------------------------|

| (i)   | the                content of this Agreement to Third Party contractors or collaborators                to                facilitate or carry out research, development or commercialization                activities under this Agreement or to carry out financing arrangements;                and |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | the                University’s Confidential Information to Third Parties in the exercise of                each of Hana and INEX’s rights under this                Agreement; |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (iii)   | the                securities laws of any relevant jurisdiction, including the Recipient’s                jurisdiction of incorporation or a jurisdiction in which the Recipient’s                securities are traded on a stock exchange;                or |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (iv)   | such                disclosure is required to be made by the Recipient or its Representatives                under the terms of a valid and effective subpoena or order issued                by a                court of competent jurisdiction or by an administrative body or government                authority; |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (v)   | the                Recipient shall immediately notify the Discloser prior to any such                disclosure and the Discloser shall have been given the opportunity                where                possible to oppose such disclosure by the Recipient by seeking a                protective order or other appropriate remedy, or to waive compliance                with                the provisions of this Agreement; |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (vi)   | the                Recipient or its Representatives, as the case may be, shall disclose                only                that portion of the Information legally required to be disclosed;                and |
|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (vii)   | the                Recipient or its Representatives, as the case may be, will exercise                all                reasonable efforts to maintain the confidential treatment of the                Information. |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**9.5  **
**Liability        for Representatives**

**9.6  **
**No        Limitation on Regulatory Compliance**

----

**9.7  **
**Return        of Confidential Information**

**Article      10**
** **
**PRODUCTION      AND MARKETING**

**10.1        N**
**o      Use of Names and Trademarks**

| (a)   | Hana                shall not use any of the UBC Trade-marks or make reference to the                University or its name or to INEX in any advertising or publicity                whatsoever, without the prior written consent of the University or                INEX,                respectively, except as required by law. INEX shall not make reference                to                Hana in any advertising or publicity whatsoever, without the prior                written                consent of Hana, except as required by law. Without limiting the                generality of the foregoing, neither Party shall issue a press release                with respect to this Agreement or any activity contemplated herein                without                the prior review and approval of same by the other Party, except                as                required by law. If either Party is required by law to act in                contravention of this Section, such Party shall provide the other                Party                with sufficient advance notice in writing to permit the other Party                to                bring an application or other proceeding to contest the                requirement. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | Hana                at its sole cost and expense, shall be responsible for the selection,                registration and maintenance of all trademarks which it employs in                connection with Sphingosomal Vinorelbine and Sphingosomal Topotecan                in the                Territory and shall own and control such trademarks during the term                of                this Agreement and following its termination or expiration. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**10.2        **
**Labeling      and Patent Marking**

**10.3        **
**Development      and Commercialization Efforts**
** **

| (a)   | In                each country in the Territory in which a Product has received Regulatory                Approval, Hana, directly or through its permitted Representatives,                shall                use Commercially Reasonable Efforts to Commercialize the Product                and to                meet or cause to be met the market demand for the                Product. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | If                the University is of the view that Hana is in breach of Section                10.3(a),                INEX shall notify Hana and the Parties hereto shall appoint a mutually                acceptable person as an independent evaluator (the “**Evaluator**”)                to conduct the evaluation set forth in Section 10.3(c).                If the Parties cannot agree on such an evaluator, the appointing                authority                shall be the British Columbia International Commercial Arbitration                Centre. |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (c)   | Unless                the Parties mutually agree otherwise, the following rules and procedures                shall govern the conduct of the Parties and the Evaluator before                and                during the investigation by the                Evaluator: |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | within                thirty (30) days of the appointment of the Evaluator, each Party                shall                provide to the Evaluator and the other Party copies of all documents,                statements and records on which the Party intends to rely in presenting                its position to the Evaluator; |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | within                forty-five (45) days of the appointment of the Evaluator, Hana shall                provide to the Evaluator and INEX a written summary of its position.                On                receipt of Hana's summary, INEX shall have fifteen (15) days to prepare                and submit to Hana and the Evaluator its own summary in reply to                the                summary submitted by Hana; and |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (iii)   | on                receipt of the documents, statements, records and summaries submitted                by                the Parties the Evaluator shall have thirty (30) days within which                to                conduct such further inquiries as he or she may deem necessary for                the                purpose of reviewing the efforts made by Hana with respect to the                promotion, marketing and sale of the Product in compliance with the                requirements of Section 10.3(a).                For the purpose of conducting such an inquiry, the Evaluator shall                have                the right to: |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (A)   | require                either Party to disclose any further documents or records which the                Evaluator considers to be relevant; |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------|

| (B)   | interview                or question either orally (or by way of written questions) one or                more                Representatives of either Party on issues deemed to be relevant by                the                Evaluator; |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (C)   | make                an "*on                site*"                inspection of Hana’s facilities; |
|-----------------|---------------------------------------------------------------------------------------------------------|

| (D)   | obtain                if necessary, the assistance of an independent expert to provide                technical                information with respect to any area in which the Evaluator does                not have                a specific expertise. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (d)   | The                Evaluator shall within thirty (30) days of starting the inquiry,                prepare a                report setting out his or her findings and conclusions as to whether                or                not Hana has used Commercially Reasonable Efforts as specified in                Section                10.3(a).                If the Evaluator determines that Hana has failed to use Commercially                Reasonable Efforts as specified in Section 10.3(a),                then the Evaluator shall specify in the report his or her conclusions                as                to what would constitute such efforts, and Hana shall thereafter                make the                efforts so specified. If Hana fails to make such efforts, after notice                of                termination for breach provided in accordance with the terms of Section                17.4,                then INEX’s sole remedy for failure to make the efforts specified in                Section 10.3(a)                and 10.3(d)                shall be that this Agreement may be terminated in accordance with                Section                17.4. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (e)   | The                report and conclusions of the Evaluator shall be delivered to Hana                and                INEX, and shall be accepted by both Parties as final and                binding. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (f)   | INEX                may not call for more than one evaluation pursuant to Section 10.3(b)                in                any two (2) calendar year period. The cost of an evaluation hereunder                shall be borne [***]%                by Hana and [***]%                by INEX. At the request of Hana, INEX will consent to the participation                in                any evaluation made pursuant hereto of Hana’s Sublicensee(s). At the                request of INEX, Hana will participate in an evaluation made pursuant                to                Article 10 of the UBC License. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (g)   | Hana                agrees that it shall deliver to INEX an annual report, due on December                31                of each year during the term of this Agreement, which summarizes                the major                activities Hana has undertaken in the course of the preceding twelve                (12)                months to develop and commercialize and/or market the Technology                in the                Hana Field. The report will include an outline of the status of any                Product in clinical trials and the existence of any sublicenses of                the                Technology. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**10.4  **
**Consequence        of No Sales**

| (a)   | In                addition to the terms of Section 10.3,                Hana shall be deemed to have breached its obligation to use Commercially                Reasonable Efforts in conducting marketing of a Product in any country                in                the Major Markets if, for a continuous period of one hundred and                eighty                (180) days at any time following launch of commercial sales of the                Product                in any such country in the Major Markets, no sales of the Product                are made                in the ordinary course of business in such country by Hana, an Affiliate                or a Sublicensee, unless: |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | the                Parties mutually agree it is to their mutual benefit to delay commercial                sales of Product in such country;                or |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | Hana                is prevented, restricted, interfered with or delayed in making such                sales                by reason of a cause beyond Hana’s reasonable control and can demonstrate                same to INEX; |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | If                Hana breaches its obligation set forth in Section 10.4(a): |
|-----------------|------------------------------------------------------------------------------|

| (i)   | INEX                shall be entitled to terminate all rights granted to Hana in the                Definitive Agreements in respect of such Product in such country                in the                Major Markets by written notice to Hana in the event that Hana is                in                default of its obligations under Section 10.4(a)                and fails to remedy such default within sixty (60) days after notice                thereof by INEX; |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | All                sublicenses granted by Hana in respect of such Product in such country                in                the Major Markets shall forthwith terminate upon the effective date                of                termination in Section 10.4(b)(i);                and |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (iii)   | Hana                shall continue to be bound by and shall comply with Sections 17.6,                17.7                and any other Sections which are intended to survive any termination                of                rights under this Agreement. |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**10.5  **
**Reports        on Commercialization**

| (a)   | Hana                shall deliver to INEX within thirty (30) days after the end of each                Calendar Quarter reports setting forth in general terms, reasonably                sufficient for evaluation of the diligence obligations contained                herein,                the efforts Hana has made to Commercialize the Product during the                year,                including any significant adverse developments, and any plans for                or                occurrences of any commercial sales of the Product in any jurisdiction                and                a summary of the efforts it intends to make in the upcoming year(s)                on                these matters.                Hana agrees to appropriately consider any INEX input and comments                related                to Hana’s plan for the upcoming year(s), provided that it is understood                that Hana shall have final decision making responsibility for such                plans. |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (b)   | To                the extent that such could not be appropriately communicated to INEX                in                accordance with Section 10.5(a),                Hana shall keep INEX informed in a timely manner of significant                developments in Hana’s (and its Affiliates and Sublicensees where                relevant) progress of its efforts to Commercialize the Product, including                without limitation, any significant adverse developments, and any                plans                for or occurrences of any commercial sales of the Product in any                jurisdiction. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**10.6  **
**Development        Plans**

| (a)   | Hana,                with INEX’ assistance, shall prepare for the Parties’ review and                discussion, a detailed Development Plan for the Development of each                Product. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | The                Development Plan shall describe the specific Clinical Activities,                Regulatory Activities, Technical Transfer activities, and Manufacturing                activities to be performed in the Territory for the                twelve (12) month period                following the Effective Date. The                Development Plan will be reviewed from time to time as the Parties                reasonably determine to be necessary or                useful. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | The                Development Plan shall be incorporated herein by reference and all                Development shall be conducted by Hana                in                compliance with Regulatory                Requirements. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**10.7  **
**Reports        on Development**

| (a)   | Hana                shall use Commercially Reasonable Efforts to Develop each Product                in the                Territory (including carrying out its responsibilities under the                Development Plan) to: |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | conduct                or cause to be conducted the necessary and appropriate clinical trials                as                necessary to obtain and maintain Regulatory Approvals for each Product;                and |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | prepare,                file and prosecute or cause to be prepared, filed and prosecuted                the                Regulatory Submission for each                Product. |
|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | Hana                will provide INEX with written reports to keep INEX fully informed                of the                progress of the Development of each Product as                follows: |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | at                the close of each Calendar Quarter during the first twenty-four (24)                months following the Effective Date;                and |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | on                or before June 31 and December 31 of each and every calendar year                thereafter. |
|------------------|----------------------------------------------------------------------------------------------------------------|

| (c)   | Hana                shall permit INEX to forward to UBC, copies of all reports provided                by                Hana to INEX pursuant to this Section 10.5, 10.6 and 10.7(b). |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**10.8  **
**Regulatory        Compliance**

----

**Article      11**
** **
**ACCOUNTING      RECORDS**

**11.1        **
**Documentation**

**11.2        **
**Reporting**

| (a)   | Hana                shall deliver the Accounting to the University on the date sixty                (60) days                after each and every Royalty Due Date, together with the Royalty                Due UBC                payable hereunder and the Accounting (and a report identifying each                Sublicensee and the principal location of the business of each                Sublicensee); and |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | Hana                shall                deliver to INEX within thirty (30) days after the end of each Calendar                Quarter a written report showing its computation                of Royalty Due INEX under this Agreement upon Net Sales by Hana and                its                Affiliates and its Sublicensees during such Calendar Quarter, and                setting                out: |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | all                Net Sales segmented in each such report according to sales by Hana,                each                Affiliate and each Sublicensee, as well as on a country-by-country                basis,                and month-by-month basis; |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | deductions                from gross revenues by the categories for same set out in the definition                of Net Sales; and |
|------------------|-------------------------------------------------------------------------------------------------------------------------------------|

| (iii)   | the                rates of exchange used to convert such royalties to US Dollars from                the                currency in which such sales were made. For the purposes hereof,                such                conversion calculations are to be made on a monthly basis and the                rates of                exchange to be used for converting royalties hereunder to US Dollars                shall                be those in effect for the purchase of US Dollars as certified by                the noon                buying rate of the Federal Reserve Bank of New York on the first                Business                Day of the Calendar Quarter with respect to which the payment is                due; |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | Hana’s                payment of Sublicensing Revenue Due INEX and all Royalty Due UBC                under                this Agreement shall be accompanied by an accounting setting out                all                Sublicensing Revenue Due INEX and Sublicensing Revenue Due UBC payable                to,                collected or received by Hana or its Affiliates, segmented according                to                Product, Sublicensee identified by name, and the last date on which                each                Sublicense Agreement was executed.. |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**11.3**
**Method      of Calculation**

**11.4**
**Record      Retention**

----

**11.5**
**Confidential      Treatment**

**Article      12**
** **
**INSURANCE**

**12.1  **
**Insurance**

| (a)   | Prior                to or immediately upon the start of any human clinical trials or                other                product testing involving human subjects by Hana or its Sublicensee                (“**Human                Clinical Trials**”)                and for a period of five (5) years after the expiration of this Agreement                or the earlier termination thereof, Hana shall obtain and/or maintain,                respectively, at its sole cost and expense, public liability and                product                liability insurance in not less than the following amounts, with                a                reputable and financially secure insurance                carrier: |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | Each                Occurrence:    $5,000,000                Dollars |
|-----------------|-------------------------------------------------------------------------------------|

| (ii)   | General                Aggregate: $5,000,000                Dollars |
|------------------|---------------------------------------------------------------------|

| (b)   | At                all times during the term of this Agreement and for a period of five                (5)                years after the expiration of this Agreement or the earlier termination                thereof, INEX shall obtain and/or maintain, respectively, at its                sole cost                and expense, comprehensive or commercial form general liability coverage,                including contractual liability, and public liability insurance in                not                less than the following amounts, with a reputable and financially                secure                insurance carrier: |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | Each                Occurrence:    $4,000,000                (Canadian dollars) |
|-----------------|-----------------------------------------------------------------------------------------------------|

| (ii)   | General                Aggregate: $4,000,000                (Canadian dollars) |
|------------------|--------------------------------------------------------------------------------|

| (c)   | INEX                shall, at Hana’s request, provide Hana with certificates of insurance and                copies of the policies of insurance reflecting the coverage and amounts                set forth in this Section 12.6.2. Each certificate of insurance shall                contain a provision that the coverage afforded under the policy(s)                will                not be cancelled without thirty (30) days prior written notice (hand                delivered or certified mail, return receipt requested) to                Hana. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (d)   | Hana’s                insurance shall include the University, its Board of Governors, faculty,                officers, employees, students and agents as additional insureds,                and shall                provide primary coverage with respect to the activities contemplated                by                this Agreement. Such policy shall not be cancelled or materially                altered                except upon at least thirty (30) days’ written notice to INEX and UBC.                Failing the Parties’ agreeing on the appropriate terms or the amount of                coverage, then the matter shall be determined as provided in Section                14.3                herein. Hana shall provide INEX with certificates of insurance evidencing                such coverage thirty (30) days before commencement of Human Clinical                Trials and thirty (30) days prior to the sales of any Product, and                Hana                covenants not to start Human Clinical Trials, or sell any Product                before                such certificate is provided and approved by INEX, or to start any                Human                Clinical Trials or sell any Product at any time unless the insurance                outlined in this Article                12                is                in effect. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (e)   | Each                Party shall require that such Party’s Representatives and Hana’s                Sublicensee under this Agreement shall                either: |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | demonstrate                to the other Party’s reasonable satisfaction that such Representative or                Hana’s Sublicensee has a program of self insurance no less adequate than                that which a reasonable and prudent businessperson carrying on a                similar                line of business would require; or |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | sixty                (60) days prior to the earlier of the start of Human Clinical Trials                or                the first sale of any Product by Hana’s Sublicensee, procure and maintain                public liability, and product liability insurance in reasonable amounts,                with a reputable and financially secure insurance carrier. Hana shall                ensure that any and all such policies of insurance required pursuant                to                this Article                12                shall contain a waiver of subrogation against the University, its                Board of                Governors, faculty, officers, employees, students, and                agents. |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (f)   | Notwithstanding                anything to the contrary contained in this Section 12.1,                before                the first date of commercial sale of any Product in the U.S., Hana                and its                Affiliate and Sublicensee of each such Product will maintain in full                force                and effect, with reputable insurers or pursuant to a self-insurance                program, product liability insurance to a minimum value of Five Million                Dollars ($5,000,000) per each occurrence and in the                aggregate. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Article      13**
** **
**ASSIGNMENT**

**13.1  **
**Assignment**
** **

| (a)   | Except                as expressly permitted hereby, Hana will not assign, transfer, mortgage,                charge or otherwise dispose of any or all of the rights, duties or                obligations granted to it under this Agreement without the prior                written                consent of the University and INEX, the consent of INEX not to be                unreasonably withheld or delayed. INEX shall reasonably co-operate                with                and assist Hana in obtaining the consent of the University to any                proposed                assignment of this Agreement by Hana. Notwithstanding the foregoing,                Hana                shall have the right to assign to an Affiliated Company or an entity                that                acquires all or substantially all of the assets related to the Technology                and the Product. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | Hana                acknowledges that the University shall have the right to assign its                rights, duties and obligations under the UBC License to a company                or                society of which the University is the sole shareholder in the case                of a                company or of which the University controls the membership, in the                case of                a society. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**Article      14**
** **
**GOVERNING      LAW AND ARBITRATION**

**14.1  **
**Governing        Law**

**14.2  **
**Jurisdiction**

**14.3**
**Arbitration**

| (a)   | Prior                to engaging in any formal dispute resolution with respect to any                dispute,                controversy or claim arising out of or in relation to this Agreement                or                the breach, termination or invalidity of this Agreement (each, a                “**Dispute**”),                the Chief Executive Officers of the Parties shall attempt to resolve                the                Dispute for a period not less than thirty (30)                days. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | Except                for any Dispute with respect to Intellectual Property Rights, which                may,                at the option of the other Party, be dealt with by commencing an                action in                a court of competent jurisdiction, any Dispute that cannot be settled                amicably by agreement of the Parties pursuant to Section 14.3(a)                may, on mutual agreement of the Parties, be finally settled by a                single                arbitrator appointed [pursuant to the provisions of the CPR                International Institute for Conflict Prevention & Resolution] [in                accordance with the rules of the American Arbitration                Association]. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | The                place of arbitration shall be Vancouver and the language to be used                in the                arbitration proceedings shall be                English. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (d)   | The                award rendered in any arbitration shall be final and binding upon                both                Parties. The judgment rendered by the arbitrator(s) shall include                costs of                arbitration, reasonable legal fees and reasonable costs for any expert                and                other witnesses. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (e)   | Notwithstanding                the provisions of Sections 14.3(a),                14.3(b),                14.3(c),                14.3(d)                and 14.3**Error!                Reference source not found.**,                either Party shall be free to submit any Dispute relating to Intellectual                Property Rights to any court having jurisdiction over the Parties                and the                subject matter of the Dispute and to seek such relief and remedies                as are                available in that court. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (f)   | Each                Party is required to continue to perform its obligations under this                Agreement pending final resolution of any                Dispute. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (g)   | Notwithstanding                any provision of this Article                14,                if a ruling by a court or arbitral authority on any dispute between                INEX                and Hana regarding the interpretation of this Agreement could reasonably                affect the interpretation of the UBC License, the Parties acknowledge                that                under the UBC License, on receipt of notice of such a dispute from                INEX,                the University may elect to apply to join in such proceeding in accordance                with the UBC License. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (h)   | Notwithstanding                any provision of this Article                14,                if a ruling by a court or arbitral authority on any dispute between                Hana                and its Sublicensee regarding the interpretation of the Sublicensee's                Sublicense                Agreement                could reasonably affect the interpretation of this Agreement, on                receipt                of notice of such a dispute from Hana, INEX may elect to apply to                join in                such proceeding. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | If                INEX is permitted to join in such proceeding it shall be bound by                the                decision of such court or arbitral authority, in so far as the                interpretation of such decision could reasonably affect the interpretation                of this Agreement. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | If                INEX elects not to join in such proceeding (for reasons other than                not                being permitted to join) then INEX hereby agrees to be bound by the                decision of such court or arbitral authority, in so far as the                interpretation of such decision could reasonably affect the interpretation                of this Agreement. |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (iii)   | If                INEX is not permitted to join in such proceeding, then INEX shall                not be                bound by the decision of such court or arbitral                authority. |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Article      15**
** **
**NOTICES**

**15.1  **
**Notices**

| If                to INEX: Inex                Pharmaceuticals Corporation#250                - 8900 Glenlyon ParkwayBurnaby,                B.C.Canada                V5J 5J8 Attention:                 President                and CEO Tel: (604)                419-3200Fax: (604)                419-3202 | With                a copy to: Lang                Michener LLP1500                - 1055 West Georgia StreetVancouver,                B.C.V6E                4N7 Attention:                Leo Raffin Tel:                 (604)                691-7450Fax: (604)                685-7084 |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| If                to Hana: Hana                BioSciences, Inc.400                Oyster Point Boulevard, Suite 215,South                San Francisco, CA 94080U.S.A Attention:                 President                and/or CEO Tel: Fax:  | With                a copy to:  Attention:                 Tel:                 Fax:  |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|

**Article      16**
** **
**TERM**

**16.1  **
**Term**

| (a)   | In                respect of any Royalty Due UBC, this Agreement and the sublicense                granted                hereunder shall terminate on the expiration of a term of twenty (20)                years                from July 1, 1998 or the expiration of the last patent obtained pursuant                to Article                6                herein, whichever event shall last occur unless earlier terminated                pursuant to Article                17                herein. Upon expiry of the Term of this Agreement (but not on termination                in accordance with Article                17)                Hana shall thereafter have, in perpetuity, a fully paid-up worldwide                license to use and sublicense the Technology in the Hana Field and                to                Manufacture, have made, distribute, import, use and sell Products,                without                further payment of Royalty Due UBC. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | Notwithstanding                the termination or expiration of the Term of this Agreement, Hana                shall                continue to make payment to INEX in accordance with the principles                set                forth in the Definitive Agreements. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Article      17**
** **
**TERMINATION**

**17.1        **
**Termination      for Bankruptcy**

| (a)   | This                Agreement may be terminated by INEX by providing notice to Hana                upon: |
|-----------------|----------------------------------------------------------------------------------------------------------|

| (i)   | the                bankruptcy, liquidation or dissolution of                Hana; |
|-----------------|-----------------------------------------------------------------------------------|

| (ii)   | the                filing of any voluntary petition for bankruptcy, dissolution, liquidation                or winding-up of the affairs of Hana;                or |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (iii)   | the                filing of any involuntary petition for bankruptcy, dissolution,                liquidation or winding-up of the affairs of Hana which is not dismissed                within one hundred twenty (120) days after the date on which it is                filed                or commenced. |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | This                Agreement may be terminated by Hana by providing written notice to                INEX                upon: |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------|

| (i)   | the                bankruptcy, liquidation or dissolution of                INEX; |
|-----------------|-----------------------------------------------------------------------------------|

----

| (ii)   | the                filing of any voluntary petition for bankruptcy, dissolution, liquidation                or winding-up of the affairs of INEX;                or |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (iii)   | the                filing of any involuntary petition for bankruptcy, dissolution,                liquidation or winding-up of the affairs of INEX which is not dismissed                within one hundred twenty (120) days after the date on which it is                filed                or commenced. Notwithstanding                the bankruptcy of INEX, or the impairment of performance by INEX                of its                obligations under this Agreement as a result of bankruptcy of INEX,                to the                extent that INEX retains the rights necessary to grant the sublicenses                granted in this Agreement, Hana                shall be entitled to retain the sublicenses granted herein, subject                to                INEX’s rights to terminate this Agreement as provided in this                Agreement. |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | Effect                of INEX Bankruptcy. In                the event INEX shall: (1) make an assignment for the benefit of creditors,                or petition or apply to any tribunal for the appointment of a custodian,                receiver, or trustee for all or a substantial part of its assets;                (2)                commence any proceeding under any bankruptcy, dissolution,                or liquidation law or statute of any jurisdiction whether now or                hereafter                in effect; (3) have had any such petition or application filed or                any such                proceeding commenced against it in which an order for relief is entered                or                an adjudication or appointment is made, and which remains undismissed                for                a period of one hundred twenty (120) calendar days or more; (4) take                any                corporate action indicating its consent to, approval of, or acquiescence                in any such petition, application, proceeding, or order for relief                or the                appointment of a custodian, receiver, or trustee for all or substantial                part of its assets; or (5) permit any such custodianship, receivership,                or                trusteeship to continue undischarged for a period of one hundred                twenty                (120) calendar days or more (each, a “Bankruptcy Action: and the                occurrence of any of the foregoing causes the                applicable Party or any third party, including, without limitation,                a                trustee in bankruptcy, to be empowered under state or federal law                to                reject this Agreement or any Agreement supplementary hereto,                then                Hana shall have the following                rights: |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | In                the event of a rejection of this Agreement or any Agreement supplementary                hereto, Hana shall be permitted to receive and use any INEX Technology                and                Confidential Information for the purpose of enabling it to mitigate                damages caused to Hana because of the rejection of this                Agreement; |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | In                the event of a rejection of this Agreement or any agreement supplementary                hereto, Hana may elect to retain its rights under this Agreement                or any                agreement supplementary hereto as provided in Section 365(n) of the                United                States Bankruptcy Code or comparable provision of the laws of any                other                country in the Territory. Upon Hana’s written request to INEX or the                bankruptcy trustee or receiver, INEX or such bankruptcy trustee or                receiver shall not interfere with the rights of Hana as provided                in this                Agreement or in any agreement supplementary                hereto; |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (iii)   | In                the event of a rejection of this Agreement or any agreement supplementary                hereto, Hana may elect to retain its rights under this Agreement                or any                agreement supplementary hereto as provided in Section 365(n) of the                United                States Bankruptcy Code or comparable provision of the laws of any                other                country in the Territory without prejudice to any of its rights of                setoff                and/or recoupment with respect to this Agreement under the Bankruptcy                Code                or applicable non-bankruptcy law;                or |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (iv)   | In                the event of a rejection of this Agreement or any agreement supplementary                hereto, Hana may retain its rights under this Agreement or any agreement                supplementary hereto as provided in Section 365(n) of the United                States                Bankruptcy Code or comparable provision of the laws of any other                country                in the Territory without prejudice to any of its rights under Section                503(b) of the Bankruptcy Code or comparable provision of the laws                of any                other country in the Territory. |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (v)   | INEX                will provide Hana with thirty (30) days prior written notice of INEX’s                regulatory filings in respect of any reorganization or arrangement                proposed by INEX; |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (vi)   | any                reorganization or arrangement involving INEX, its affiliates and/or                its                wholly owned subsidiaries which does not prejudice the rights of                Hana                shall not constitute a Bankruptcy Action for the purposes of this                Section                17.1(c)and                shall not give rise to the remedies set forth in this Section 17.1(c);                and |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (vii)   | if                Hana asserts any rights under Sections 17.1(c)(i),                17.1(c)(ii),                17.1(c)(iii)                or                17.1(c)(iv),                Hana shall continue to be bound by all liabilities and obligations                imposed                upon Hana, its Affiliates and Sublicensees under this Agreement,                and                INEX’s custodian, receiver or trustee in bankruptcy shall be entitled                to                exercise against Hana, its Affiliates and Sublicensees, any remedies                available to INEX under this                Agreement |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**17.2        **
**Termination      by INEX**

| (a)   | if                any execution, sequestration, or any other process of any court becomes                enforceable against Hana or if any such process is levied on the                rights                under this Agreement or upon any of the monies due to INEX and is                not                released or satisfied by Hana within sixty (60) days                thereafter; |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | if                any resolution is passed by Hana or voluntary order made or other                steps                taken by Hana for the winding up, liquidation or other termination                of the                existence of Hana; |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | if                Hana ceases to carry on its business, other than as a result of a                disposition of substantially all of Hana’s business to a Third                Party; |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (d)   | if                Hana commits any breach of Section 4.1                or                any material breach of Article                12; |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------|

| (e)   | Hana                notifies INEX in writing that it intends to discontinue pursuing                all                Patent protection for the Technology hereof;                or |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (f)   | if                any Sublicensee of Hana is in material breach of its Sublicense                Agreement                with Hana which breach would be a breach of this Agreement if committed                by                Hana and Hana fails to use reasonable efforts to cause such Sublicensee                to                cure such breach within sixty (60) days of receipt of written notice                from                INEX requiring that Hana cause such Sublicensee to cure such                breach. |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**17.3        **
**Termination      for Invalidity Challenge**

**17.4        **
**Termination      for Material Breach**

| (a)   | Either                Party shall be entitled to terminate this Agreement by written notice                to                the other Party in the event that the other Party is in material                default                of any of its obligations hereunder and fails to remedy any such                breach of                its obligations within ninety (90) days after notice thereof by the                Party                alleging breach. Any such notice                shall: |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | specifically                state that the Party not in default intends to terminate this Agreement                in                the event that the other Party fails to remedy the breach;                and |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | expressly                set forth the actions required of the other Party to remedy the                breach. |
|------------------|-----------------------------------------------------------------------------------------------------------------|

| (b)   | Either                Party shall be entitled to terminate this Agreement or the licenses                granted to the other Party hereunder by written notice to such other                Party                in the event that such other Party is in material breach of the                Non-Competition Terms, and fails to remedy any such breach within                ninety                (90) days after notice thereof. |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | If                a dispute arises as to whether either Party is in material breach                of its                obligations hereunder, or as to whether such Party has cured any                such                breach, either Party may invoke the dispute resolution procedure                described                in Section 14.3                to                resolve such Dispute. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**17.5        **
**No      Limitation on Remedies**

**17.6        **
**Consequence      of Termination**

| (a)   | If                this Agreement or the license(s) granted by INEX to Hana in respect                of a                particular Product in a particular country(ies) is terminated pursuant                to                Sections 17.1(a),                17.2,                17.3                for invalidity challenge or a breach by Hana as set forth in Section                10.4                for lack of sales, or 17.4                for material breach, Hana shall make payments to each of INEX and                the                University in the manner specified in Article                5,                and each of INEX and the University, may proceed to enforce payment                of: |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | all                outstanding Royalty Due INEX, Sublicensing Revenue Due INEX and other                monies owed to INEX; and |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------|

----

| (ii)   | all                outstanding Royalty Due UBC; |
|------------------|-------------------------------------------------|

| (b)   | Upon                any such termination of this Agreement or of the license(s) granted                by                INEX to Hana, all sublicenses granted hereunder shall forthwith terminate,                and Hana shall:  |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | except                as required by law or expressly permitted by Section 17.7,                deliver up to INEX within a reasonable time, not to exceed six (6)                months                from the Effective Date of Termination, all Technology in its possession                or control and shall thereafter have no further right of any nature                whatsoever in the Technology. On failure by Hana to so deliver up                the                Technology, INEX may take action against Hana to enforce such delivery                and                Hana will pay all charges or expenses incurred by INEX in the enforcement                of such rights or remedies against Hana including, without limitation,                INEX’s legal fees and disbursements on an indemnity                basis; |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | deliver                to INEX within thirty (30) days of the Effective Date of Termination                a                written Accounting and plan specifying, in such terms as INEX may                in its                reasonable discretion require, the inventory of Product remaining                unsold                on the Effective Date of Termination, and Hana’s plan for the disposition                of same. Following the delivery of such accounting and plan, Hana                shall                then have a reasonable time to liquidate such inventory of Product,                provided that such period shall not exceed six (6) months from the                Effective Date of Termination. Hana shall continue to make all payments                to                INEX on all such Product sold in the same manner as specified in                this                Agreement, notwithstanding anything contained in, or any exercise                of                rights by INEX under this Article                17; |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (iii)   | provided                that INEX shall be responsible for any reasonable associated out-of-pocket                costs associated with the following activities, Hana shall promptly                deliver to INEX a copy of all data (including animal and human data)                and                such other information, Material, materials (including biological                materials) and documents in Hana’s possession or control arising from the                Development of Product under this Agreement that INEX may reasonably                require in order to obtain and/or maintain Regulatory Approvals.                INEX                may, directly or through a licensee, exploit such data, other information,                Materials, materials (including biological materials) and documents                to                develop, make, have made, import, use, offer for sale and sell Product                in                such country(ies);  |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (iv)   | Hana                shall also, within thirty (30) days after the effective date of such                termination, use all reasonable endeavors to take all steps and execute                all documents reasonably necessary to assign and/or transfer or permit                reference to (to the extent legally permissible in the relevant country)                all Regulatory Submissions and Regulatory Approvals arising from                the                Development of Product under this Agreement in Hana’s name or in the name                of Hana’s Representatives to INEX or its designee, provided that INEX                shall be responsible for any reasonable associated out-of-pocket                costs of                transfer; |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (v)   | In                the event that no such assignment and/or transfer and/or reference                pursuant to Section 17.6(b)(iv)                may legally be made, then Hana shall forthwith surrender to INEX                or its                designee such Regulatory Submissions and Regulatory Approvals for                cancellation; |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (vi)   | Upon                INEX’s request, Hana shall within thirty (30) days after the effective                date of such termination, deliver to INEX or its designee any and                all                documents relating to applications, correspondences with Regulatory                Authorities, Regulatory Submissions, Regulatory Approvals, and                post-Regulatory Approval Pharmacovigilance in its possession or control                arising from the Development of Product that are reasonably required                for                commercialization of Product, provided that INEX shall be responsible                for                any reasonable associated out-of-pocket costs of                transfer. |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | Upon                any termination by INEX of the licenses granted                hereunder: |
|-----------------|-----------------------------------------------------------------------------------------------|

| (i)   | Hana                shall not be relieved of any obligations incurred prior to such                termination; and |
|-----------------|---------------------------------------------------------------------------------------------------------------------|

| (ii)   | each                Party shall promptly return to the other Party all written Confidential                Information, and all copies thereof (except for one archival copy                to be                retained solely for the purpose of confirming which information to                hold in                confidence hereunder); and |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (d)   | The                termination of the license granted hereunder will be without prejudice                to: |
|-----------------|--------------------------------------------------------------------------------------------------------------|

| (i)   | INEX’s                right to receive all payments accrued from Hana pursuant to Section                6.9                as                of the effective date of such termination including, without limitation,                payment for all out-of-pocket costs and personnel costs which INEX                has                properly and reasonably incurred in providing IP Services and in                following                instructions received from Hana up to the date of such termination.                For                greater certainty, such costs shall include INEX’                reasonable and necessary non-cancelable obligations to                Third Parties actually incurred by INEX in the performance of its                obligations under this Agreement                prior to the date of notice of termination, but arising after the                date of                notice of termination; and |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | any                or all of the rights and remedies contained herein or otherwise available                to either Party by law or in equity, successively or concurrently,                at the                option of either Party. |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (e)   | Notwithstanding                the termination of this Agreement, Article                11                shall remain in full force and effect until three (3) years                after: |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | all                payments of Royalties required to be made by Hana under this Agreement                have been made by Hana to each of INEX and the University;                and |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | any                other claim or claims of any nature or kind whatsoever of INEX against                Hana has been settled. |
|------------------|---------------------------------------------------------------------------------------------------------------------------------|

----

**17.7  **
**Return        of Confidential Information**

**Article      18**
** **
**MISCELLANEOUS      COVENANTS REQUIRED BY UNIVERSITY**

**18.1        **
**Miscellaneous      Covenants of Hana**

| (a)   | Hana                hereby represents and warrants to INEX that Hana is a corporation                duly                organized, existing, and in good standing under the laws of Canada                and has                the power, authority, and capacity to enter into this Agreement and                to                carry out the transactions contemplated by this Agreement, all of                which                have been duly and validly authorized by all requisite corporate                proceedings. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | Hana                represents and warrants that it has the expertise necessary to handle                the                Technology in the Hana Field with care and without danger to Hana,                its                employees, agents, or the public. Hana shall not accept delivery                of the                Technology until it has requested and received from INEX all necessary                information and advice to ensure that it is capable of handling the                Technology in a safe and prudent                manner. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | Hana                shall comply with all laws, regulations and ordinances, whether Federal,                Provincial, Municipal or otherwise with respect to the Technology                and/or                this Agreement. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (d)   | Upon                the presentation of itemized bills to Hana by INEX or the University,                Hana                shall pay to INEX or the University, as the case may be:  |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | all                reasonable legal expenses and costs incurred by the University in                respect                of the negotiation and preparation of this Agreement, and of any                amendments of this Agreement; and |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | all                reasonable legal expenses and costs in excess of $[***]                CDN                incurred by the University in respect of any consents or approvals                required from the University, including but not limited to expenses                and                costs in respect of the University’s review of each sublicense to be                granted by Hana. |
|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (e)   | Hana                shall pay all taxes and any related interest or penalty howsoever                designated and imposed as a result of the existence or operation                of this                Agreement, including, but not limited to, tax which Hana is required                to                withhold or deduct from payments to INEX and to the University. Hana                will                furnish to INEX and to the University such evidence as may be required                by                American and Canadian authorities to establish that any such tax                has been                paid. The Royalties specified in this Agreement are exclusive of                taxes. If                INEX or the University is required to collect a tax to be paid by                Hana (or                any of its Sublicensees), Hana shall pay such tax to INEX or to the                University, as the case may be, on demand. Under                no circumstances will Hana be responsible for any franchise-related                taxes                or taxes based on the University’s or INEX’s gross or net                income |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**Article      19**
** **
**PRODUCT      SAFETY AND REGULATORY COMPLIANCE**

**19.1  **
**Regulatory        Responsibilities**

| (a)   | Hana                shall ensure                that                none of its Representatives who participate in any Development                activities: |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | is                or has been suspended, debarred or disqualified by the                FDA; |
|-----------------|----------------------------------------------------------------------------------------------|

| (ii)   | has                been convicted of any offence that would form the basis for any debarment;                or |
|------------------|-----------------------------------------------------------------------------------------------------------------|

| (iii)   | is                or has been subject to any proceedings for the suspension,                disqualification or debarment. |
|-------------------|----------------------------------------------------------------------------------------------------------------------------|

| (b)   | Upon                the re-activation and/or transfer by INEX to Hana of the NDA or IND,                as                the case may be, in respect of each Product, Hana shall be responsible                for                using                Commercially Reasonable Efforts to maintain and fulfill                all Regulatory Requirements with respect to such Product that are                imposed                upon Hana as the holder of Regulatory Submissions and Regulatory                Approvals. |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | Hana                and/or its Representatives’ Manufacturing, shipping and distribution of                Material for clinical and commercial use shall be done in accordance                with                applicable specifications and Regulatory Requirements. Hana shall                maintain                and shall require its Representatives who receive, handle, store,                ship or                distribute Product to maintain a record retention policy consistent                with                cGMP and Regulatory Requirements, and to maintain records with sufficient                detail to facilitate traceability in the event of recalls or voluntary                withdrawals of Product. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (d)   | In                respect of each Product, Hana will use Commercially                Reasonable Efforts                to                make such changes as reasonably necessary to the master production                record,                specifications, procedures, processes, Materials, facilities, equipment                or                any matter utilized by Hana under this Agreement or contained or                reference                in and documents submitted to Regulatory Authorities to meet new                Regulatory Requirements and guidelines in the                Territory. |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**19.2  **
**Pharmacovigilance**

| (a)   | Upon                the transfer~~,~~                by                INEX to Hana of the INDs for Sphingosomal Vinorelbine and Sphingosomal                Topotecan, and the NDA for Sphingosomal Vincristine, Hana shall be                responsible for, in respect of each such Product, performing                Pharmacovigilance in respect of all pre-Regulatory Approval Clinical                Activities and all post-Regulatory Approval product safety monitoring                in                accordance with Regulatory Requirements, in addition to all other                Regulatory Activities for which Hana is                responsible. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | For                as long as Material sourced, Manufactured or quality released by                INEX                remains available for use in approved clinical trials, Hana                shall: |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | inform                INEX within five (5) Business Days of any complaint received or regulatory                action taken in respect of such Material and shall seek INEX’ opinion                before passing judgment on the quality of such Material to any Third                Party; and |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | provide                INEX with a copy(ies) of all documentation provided to and received                from                Regulatory Authorities in respect of such complaint or Adverse Drug                Event,                within one (1) Business Day of sending or receiving                same. |
|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**19.3  **
**Recalls        and Product Withdrawals**

| (a)   | If                either Party is required or requested by any Regulatory Authority                to                recall or withdraw any Clinical Trial Material for any reason, or                should                either Party decide voluntarily to withdraw any Clinical Trial                Material: |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | the                Party in whose name the applicable IND file is registered will be                responsible for coordinating such recall or product                withdrawal; |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | Hana                shall pay the costs and expenses of such recall or product withdrawal,                subject to recovery of some or all of same in accordance with the                terms of                Section 19.2; |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (iii)   | Unless                INEX is liable for such costs and expenses in accordance with the                terms of                Section 19.2,                Hana will remain responsible to INEX for payment of all Services                in                respect of the Manufacture and supply of Material;                and |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (iv)   | Both                Parties will cooperate fully with one another in connection with                any such                recall or product withdrawal. |
|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | If                a recall or product withdrawal is due to INEX’s negligence, willful                misconduct or breach of this Agreement or of the Service Agreement,                INEX                will reimburse Hana for all of Hana’s reasonable costs and expenses                actually incurred by Hana in connection with the recall or product                withdrawal, including any Service fees and expenses associated with                the                supply of the Product recalled or withdrawn, costs of retrieving                Product                already delivered to customers, costs and expenses Hana is required                to pay                for notification, shipping and handling charges, destruction or return                of                the defective Product or otherwise and such other reasonable costs                as may                be reasonably related to the recall or product                withdrawal. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | If                the Parties are unable to agree on whether or not a recall or product                withdrawal is due to INEX’s negligence, willful misconduct or breach of                this Agreement, either Party may refer the matter for resolution                pursuant                to Article 13. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (d)   | Notwithstanding                any expiration or early termination of this Agreement, the provisions                of                Sections 19.2                and 19.3                shall continue to apply for as long as any Product containing Material                that was sourced, Manufactured or quality released by INEX remains                available for use in approved clinical                trials. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Article      20**
** **
**GENERAL      PROVISIONS**

**20.1  **
**UBC        Requirement**

**20.2  **
**Amendments**

----

**20.3  **
**Counterparts;        Facsimile**

**20.4  **
**Enurement**

**20.5  **
**Exhibits        / Schedules**

**20.6  **
**Force        Majeure**

**20.7  **
**Further        Assurances**

**20.8  **
**Headings**

**20.9  **
**Incorporation        by Reference**

*mutatis      mutandis*

**20.10  **
**Independent        Legal Advice**

----

**20.11  **
**Non-Use        of Names**

**20.12  **
**No        Implied Rights**

**20.13  **
**No        **
**Solicitation        or Hiring of Employees**

**20.14  **
**No        Waiver**

**20.15  **
**Publicity**

| (a)   | neither                Party, nor any of its Affiliates, shall originate any publicity,                news                release or other public announcement, written or oral, relating to                this                Agreement or the existence of an arrangement between the Parties,                without                the prior written approval of the other Party and agreement upon                the                nature and text of such announcement or disclosure, which approval                shall                not be unreasonably withheld or delayed;                and |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | the                Party desiring to make any such public announcement or other disclosure                shall inform the other Party of the proposed announcement or disclosure                in                reasonably sufficient time prior to public release, and shall provide                the                other Party with a written copy thereof, in order to allow such other                Party to comment upon such announcement or                disclosure. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**20.16  **
**Relationship        of Parties**

----

**20.17  **
**Rights        and Remedies**

**20.18  **
**Severability**

| (a)   | such                provision shall be severable from the remainder of the Agreement                in the                jurisdiction in which such provision was found to be invalid, illegal                or                unenforceable; |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | the                validity, legality and enforceability of such provision will not                in any                way be affected or impaired thereby in any other jurisdiction and                the                validity, legality and enforceability of the remaining provisions                contained herein will not in any way be affected or impaired thereby,                unless in either case as a result of such determination this Agreement                would fail in its essential purpose;                and |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | the                Parties will use their best efforts to substitute for any provision                that                is invalid, illegal or unenforceable in any jurisdiction a valid,                legal                and enforceable provision which achieves to the greatest extent possible                the economic, legal and commercial objectives of such invalid, illegal                or                unenforceable provision and of this                Agreement. |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**20.19  **
**Survival**

**20.20  **
**Wording**

**20.21  **
**Supremacy**

**IN      WITNESS WHEREOF**

| **INEX                PHARMACEUTICALS****CORPORATION**by                its authorized signatory:                       /s/ Timothy                Ruane                                      Timothy                RuanePresident                & C.E.O. | **HANA                PHARMACEUTICALS****CORPORATION**by                its authorized signatory:                         /s/ Mark J.                Ahn                                            Mark                J. AhnPresident                and C.E.O. |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**Schedule      “A” to Sublicense Agreement**

| ·   | The                Assignment of existing licences is not captured in this schedule,                which is                exclusive to IP rights only |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   **Inex                  File Number** |   **Title** |   **Serial/                  Patent Numbers** |   **Inventors** |   **Origin** |   **Ownership                  of Prosecution** |   **Hana                  Cost Allocation** |   **UBC                  Royalty** |  **UBC                  Sublicense Royalty** |
|---------------------------------------------------|-----------------------|---------------------------------------------------------|---------------------------|------------------------|-----------------------------------------------------------|-------------------------------------------------------|----------------------------------------------|---------------------------------------------------|

|  **Group                  4 (PAT-2300 and PAT-2700 families): liposome manufacturing and                  loading;                  covers all three products** |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PAT-2300-NP                                                                                                                                                          | Ionophore-Mediated                  Liposome Loading | U.S.                  Patent Application No. 08/741,622 US                  Patent Number 5,837,282ISSUED | Fenske,                  D.Cullis,                  P.Maurer,                  N.Leenhouts,                  J.Maurer,                  E.Boman,                  N. |   UBC |    INEX |    [***]% |    [***]% |    [***]% |
| PAT-2300-PCT                                                                                                                                                         | Ionophore-Mediated                  Liposome Loading | International                  Patent Application No. PCT/CA97/00821 International                  Patent Publication No.WO                  98/18450 | Fenske,                  D.Cullis,                  P.Wong,                  K.Maurer,                  N.Leenhouts,                  J.Maurer,                  E.Boman,                  N. |    UBC |    INEX |    [***]% |    [***]% |    [***]% |
| PAT-2300-AT                                                                                                                                                          | Ionophore-Mediated                  Liposome Loading | Austrian                  Patent No. AT                  0941065 GRANTED | Fenske,                  D.Cullis,                  P.Wong,                  K.Maurer,                  N.Leenhouts,                  J.Maurer,                  E.Boman,                  N. |    UBC |    INEX |    [***]% |    [***]% |    [***]% |
| PAT-2300-AU                                                                                                                                                          | Ionophore-Mediated                  Liposome Loading | Australian                  Patent No. AU                  718460 GRANTED | Fenske,                  D.Cullis,                  P.Wong,                  K.Maurer,                  N.Leenhouts,                  J.Maurer,                  E.Boman,                  N. |    UBC |    INEX |    [***]% |    [***]% |    [***]% |

----

|   **Inex                    File Number** |   **Title** |   **Serial/                    Patent Numbers** |   **Inventors** |   **Origin** |   **Ownership                    of Prosecution** |   **Hana                    Cost Allocation** |   **UBC                    Royalty** |  **UBC                    Sublicense Royalty** |
|-----------------------------------------------------|-----------------------|-----------------------------------------------------------|---------------------------|------------------------|-------------------------------------------------------------|---------------------------------------------------------|------------------------------------------------|-----------------------------------------------------|

| PAT-2300-BE | Ionophore-Mediated                  Liposome Loading | Belgium                  Patent No. BE                  0941065 GRANTED     | Fenske,                  D.Cullis,                  P.Wong,                  K.Maurer,                  N.Leenhouts,                  J.Maurer,                  E.Boman,                  N. |    UBC |    INEX |    [***]% |    [***]% |    [***]% |
|-------------|------------------------------------------------------|----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|------------------------|--------------------------|--------------------------|--------------------------|
| PAT-2300-CA | Ionophore-Mediated                  Liposome Loading | Canadian                  Patent Application No. 2,269,921 PENDING          | Fenske,                  D.Cullis,                  P.Wong,                  K.Maurer,                  N.Leenhouts,                  J.Maurer,                  E.Boman,                  N. |    UBC |    INEX |    [***]% |    [***]% |    [***]% |
| PAT-2300-CH | Ionophore-Mediated                  Liposome Loading | Switzerland                  Patent No. CH                  0941065 GRANTED | Fenske,                  D.Cullis,                  P.Wong,                  K.Maurer,                  N.Leenhouts,                  J.Maurer,                  E.Boman,                  N. |    UBC |    INEX |    [***]% |    [***]% |    [***]% |
| PAT-2300-DE | Ionophore-Mediated                  Liposome Loading | German                  Patent No. DE                  0941065 GRANTED      | Fenske,                  D.Cullis,                  P.Wong,                  K.Maurer,                  N.Leenhouts,                  J.Maurer,                  E.Boman,                  N. |    UBC |    INEX |    [***]% |    [***]% |    [***]% |

----

|   **Inex                    File Number** |   **Title** |   **Serial/                    Patent Numbers** |   **Inventors** |   **Origin** |   **Ownership                    of Prosecution** |   **Hana                    Cost Allocation** |   **UBC                    Royalty** |  **UBC                    Sublicense                    Royalty** |
|-----------------------------------------------------|-----------------------|-----------------------------------------------------------|---------------------------|------------------------|-------------------------------------------------------------|---------------------------------------------------------|------------------------------------------------|------------------------------------------------------------------------|

| PAT-2300-DK | Ionophore-Mediated                  Liposome Loading | Danish                  Patent No. DE                  0941065 GRANTED                                                                    | Fenske,                  D.Cullis,                  P.Wong,                  K.Maurer,                  N.Leenhouts,                  J.Maurer,                  E.Boman,                  N. |    UBC |    INEX |    [***]% |    [***]% |    [***]% |
|-------------|------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|------------------------|--------------------------|--------------------------|--------------------------|
| PAT-2300-EP | Ionophore-Mediated                  Liposome Loading | European                  Patent Application No. 97911086.3 European                  Patent No. EP                  0941065 GRANTED | Fenske,                  D.Cullis,                  P.Wong,                  K.Maurer,                  N.Leenhouts,                  J.Maurer,                  E.Boman,                  N. |    UBC |    INEX |    [***]% |    [***]% |    [***]% |
| PAT-2300-ES | Ionophore-Mediated                  Liposome Loading | Spanish                  Patent No. ES                  0941065 GRANTED                                                                   | Fenske,                  D.Cullis,                  P.Wong,                  K.Maurer,                  N.Leenhouts,                  J.Maurer,                  E.Boman,                  N. |    UBC |    INEX |    [***]% |    [***]% |    [***]% |
| PAT-2300-FR | Ionophore-Mediated                  Liposome Loading | French                  Patent No. FR                  0941065 GRANTED                                                                    | Fenske,                  D.Cullis,                  P.Wong,                  K.Maurer,                  N.Leenhouts,                  J.Maurer,                  E.Boman,                  N. |    UBC |    INEX |    [***]% |    [***]% |    [***]% |

----

|   **Inex                    File Number** |   **Title** |   **Serial/                    Patent Numbers** |   **Inventors** |   **Origin** |   **Ownership                    of Prosecution** |   **Hana                    Cost Allocation** |   **UBC                    Royalty** |  **UBC                    Sublicense                    Royalty** |
|-----------------------------------------------------|-----------------------|-----------------------------------------------------------|---------------------------|------------------------|-------------------------------------------------------------|---------------------------------------------------------|------------------------------------------------|------------------------------------------------------------------------|

| PAT-2300-GB | Ionophore-Mediated                  Liposome Loading | United                  Kingdom Patent No. GB                  0941065 GRANTED | Fenske,                  D.Cullis,                  P.Wong,                  K.Maurer,                  N.Leenhouts,                  J.Maurer,                  E.Boman,                  N. |    UBC |    INEX |    [***]% |    [***]% |    [***]% |
|-------------|------------------------------------------------------|-------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|------------------------|--------------------------|--------------------------|--------------------------|
| PAT-2300-IE | Ionophore-Mediated                  Liposome Loading | Irish                  Patent No. IE                  0941065 GRANTED          | Fenske,                  D.Cullis,                  P.Wong,                  K.Maurer,                  N.Leenhouts,                  J.Maurer,                  E.Boman,                  N. |    UBC |    INEX |    [***]% |    [***]% |    [***]% |
| PAT-2300-IT | Ionophore-Mediated                  Liposome Loading | Italian                  Patent No. IT                  0941065 GRANTED        | Fenske,                  D.Cullis,                  P.Wong,                  K.Maurer,                  N.Leenhouts,                  J.Maurer,                  E.Boman,                  N. |    UBC |    INEX |    [***]% |    [***]% |    [***]% |
| PAT-2300-JP | Ionophore-Mediated                  Liposome Loading | Japanese                  Patent Application No. 10-519843 PENDING             | Fenske,                  D.Cullis,                  P.Wong,                  K.Maurer,                  N.Leenhouts,                  J.Maurer,                  E.Boman,                  N. |    UBC |    INEX |    [***]% |    [***]% |    [***]% |

----

|   **Inex                    File Number** |   **Title** |   **Serial/                    Patent Numbers** |   **Inventors** |   **Origin** |   **Ownership                    of Prosecution** |   **Hana                    Cost Allocation** |   **UBC                    Royalty** |  **UBC                    Sublicense                    Royalty** |
|-----------------------------------------------------|-----------------------|-----------------------------------------------------------|---------------------------|------------------------|-------------------------------------------------------------|---------------------------------------------------------|------------------------------------------------|------------------------------------------------------------------------|

| PAT-2300-NL  | Ionophore-Mediated                  Liposome Loading                              | Netherlands                  Patent No. NL                  0941065 GRANTED                                                                     | Fenske,                  D.Cullis,                  P.Wong,                  K.Maurer,                  N.Leenhouts,                  J.Maurer,                  E.Boman,                  N. |    UBC |    INEX |    [***]% |    [***]% |    [***]% |
|--------------|-----------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|------------------------|--------------------------|--------------------------|--------------------------|
| PAT-2300-SE  | Ionophore-Mediated                  Liposome Loading                              | Swedish                  Patent No. SE                  0941065 GRANTED                                                                         | Fenske,                  D.Cullis,                  P.Wong,                  K.Maurer,                  N.Leenhouts,                  J.Maurer,                  E.Boman,                  N. |    UBC |    INEX |    [***]% |    [***]% |    [***]% |
| PAT-2700-PSP | Methods                  for Preparation of Lipid-Encapsulated Therapeutic Agents | U.S.                  Provisional Patent Application No. 60/143,978 EXPIRED                  - July 15, 2000                                    | Knopov,                  V.Dzubanov,                  K.Harper,                  K.Maurer,                  N.Wong,                  K.Cullis,                  P.                            |   UBC       |   INEX       |   [***]%       |   [***]%       |   [***]%       |
| PAT-2700-PCT | Methods                  for Preparation of Lipid-Encapsulated Therapeutic Agents | International                  Patent Application No. PCT/CA00/00843 International                  Publication No.WO                  01/05374 | Maurer,                  N.Wong,                  K.Cullis,                  P.                                                                                                               |    UBC |   INEX       |   [***]%       |   [***]%       |   [***]%       |
| PAT-2700-AU  | Methods                  for Preparation of Lipid-Encapsulated Therapeutic Agents | Australian                  Patent No. AU                  769357 GRANTED                                                                       | Maurer,                  N.Wong,                  K.Cullis,                  P.                                                                                                               |    UBC |   INEX       |   [***]%       |   [***]%       |   [***]%       |

----

|   **Inex                    File Number** |   **Title** |   **Serial/                    Patent Numbers** |   **Inventors** |   **Origin** |   **Ownership                    of Prosecution** |   **Hana                    Cost Allocation** |   **UBC                    Royalty** |  **UBC                    Sublicense                    Royalty** |
|-----------------------------------------------------|-----------------------|-----------------------------------------------------------|---------------------------|------------------------|-------------------------------------------------------------|---------------------------------------------------------|------------------------------------------------|------------------------------------------------------------------------|

| PAT-2700-BR | Methods                  for Preparation of Lipid-Encapsulated Therapeutic Agents | Brazilian                  Patent Application No. 0012624-1 PENDING                                                                       | Maurer,                  N.Wong,                  K.Cullis,                  P. |    UBC |   INEX |   [***]% |   [***]% |   [***]% |
|-------------|-----------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|-----------------------|------------------|--------------------|--------------------|--------------------|
| PAT-2700-CA | Methods                  for Preparation of Lipid-Encapsulated Therapeutic Agents | Canadian                  Patent Application No. 2,378,438 PENDING                                                                        | Maurer,                  N.Wong,                  K.Cullis,                  P. |   UBC       |   INEX |   [***]% |   [***]% |   [***]% |
| PAT-2700-CN | Methods                  for Preparation of Lipid-Encapsulated Therapeutic Agents | Chinese                  Patent No. ZL                  00810355.0 GRANTED                                                                | Maurer,                  N.Wong,                  K.Cullis,                  P. |    UBC |   INEX |   [***]% |   [***]% |   [***]% |
| PAT-2700-DE | Methods                  for Preparation of Lipid-Encapsulated Therapeutic Agents | German                  Patent No. DE                  1194122 GRANTED                                                                    | Maurer,                  N.Wong,                  K.Cullis,                  P. |    UBC |   INEX |   [***]% |   [***]% |   [***]% |
| PAT-2700-EP | Methods                  for Preparation of Lipid-Encapsulated Therapeutic Agents | European                  Patent Application No. 00949026.9 European                  Patent No. EP                  1194122 GRANTED | Maurer,                  N.Wong,                  K.Cullis,                  P. |    UBC |   INEX |   [***]% |   [***]% |   [***]% |
| PAT-2700-ES | Methods                  for Preparation of Lipid-Encapsulated Therapeutic Agents | Spanish                  Patent No. ES                  1194122 GRANTED                                                                   | Maurer,                  N.Wong,                  K.Cullis,                  P. |   UBC       |   INEX |   [***]% |   [***]% |   [***]% |

----

|   **Inex                    File Number** |   **Title** |   **Serial/                    Patent Numbers** |   **Inventors** |   **Origin** |   **Ownership                    of Prosecution** |   **Hana                    Cost Allocation** |   **UBC                    Royalty** |  **UBC                    Sublicense                    Royalty** |
|-----------------------------------------------------|-----------------------|-----------------------------------------------------------|---------------------------|------------------------|-------------------------------------------------------------|---------------------------------------------------------|------------------------------------------------|------------------------------------------------------------------------|

| PAT-2700-FR | Methods                  for Preparation of Lipid-Encapsulated Therapeutic Agents | French                  Patent No. FR                  1194122 GRANTED                                         | Maurer,                  N.Wong,                  K.Cullis,                  P. |    UBC |   INEX |   [***]% |   [***]% |   [***]% |
|-------------|-----------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|-----------------------|------------------|--------------------|--------------------|--------------------|
| PAT-2700-GB | Methods                  for Preparation of Lipid-Encapsulated Therapeutic Agents | United                  Kingdom Patent No. GB                  1194122 GRANTED                                 | Maurer,                  N.Wong,                  K.Cullis,                  P. |    UBC |   INEX |   [***]% |   [***]% |   [***]% |
| PAT-2700-IE | Methods                  for Preparation of Lipid-Encapsulated Therapeutic Agents | Irish                  Patent No. IE                  1194122 GRANTED                                          | Maurer,                  N.Wong,                  K.Cullis,                  P. |    UBC |   INEX |   [***]% |   [***]% |   [***]% |
| PAT-2700-IL | Methods                  for Preparation of Lipid-Encapsulated Therapeutic Agents | Israeli                  Patent Application No. 147,089 PENDING                                                | Maurer,                  N.Wong,                  K.Cullis,                  P. |   UBC       |   INEX |   [***]% |   [***]% |   [***]% |
| PAT-2700-IS | Methods                  for Preparation of Lipid-Encapsulated Therapeutic Agents | Icelandic                  Patent Application No. PCT/CA00/00843 ABANDONED                  - OCTOBER 19, 2004 | Maurer,                  N.Wong,                  K.Cullis,                  P. |    UBC |   INEX |   [***]% |   [***]% |   [***]% |
| PAT-2700-IT | Methods                  for Preparation of Lipid-Encapsulated Therapeutic Agents | Italian                  Patent No. IT                  1194122 GRANTED                                        | Maurer,                  N.Wong,                  K.Cullis,                  P. |    UBC |   INEX |   [***]% |   [***]% |   [***]% |

----

|   **Inex                    File Number** |   **Title** |   **Serial/                    Patent Numbers** |   **Inventors** |   **Origin** |   **Ownership                    of Prosecution** |   **Hana                    Cost Allocation** |   **UBC                    Royalty** |  **UBC                    Sublicense Royalty** |
|-----------------------------------------------------|-----------------------|-----------------------------------------------------------|---------------------------|------------------------|-------------------------------------------------------------|---------------------------------------------------------|------------------------------------------------|-----------------------------------------------------|

| PAT-2700-JP   | Methods                  for Preparation of Lipid-Encapsulated Therapeutic Agents | Japanese                  Patent Application No. 2001-510431 PENDING                                                                             | Maurer,                  N.Wong,                  K.Cullis,                  P.                 |    UBC |   INEX |   [***]% |   [***]% |   [***]% |
|---------------|-----------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|-----------------------|------------------|--------------------|--------------------|--------------------|
| PAT-2700-SG   | Methods                  for Preparation of Lipid-Encapsulated Therapeutic Agents | Singapore                  Patent No. SG                  85793 GRANTED                                                                          | Maurer,                  N.Wong,                  K.Cullis,                  P.                 |   UBC       |   INEX |   [***]% |   [***]% |   [***]% |
| PAT-2700-US   | Methods                  for Preparation of Lipid-Encapsulated Therapeutic Agents | U.S.                  Patent Application No. 10/019,199 PENDING                                                                                  | Maurer,                  N.Wong,                  K.Cullis,                  P.                 |  UBC             |   INEX |   [***]% |   [***]% |   [***]% |
| PAT-2700-PCT1 | Method                  and Apparatus for Preparation of Lipid Vesicles           | International                  Patent Application No. PCT/CA00/00842 International                  Publication No. WO                  01/05373 | Knopov,                  V.Dzubanov,                  K. Harper, K. Cullis,                  P. |   UBC       |   INEX |   [***]% |   [***]% |   [***]% |
| PAT-2700-AU1  | Method                  and Apparatus for Preparation of Lipid Vesicles           | Australian                  Patent No. AU                  771706 GRANTED                                                                        | Knopov,                  V.Dzubanov,                  K. Harper, K. Cullis,                  P. |   UBC       |   INEX |   [***]% |   [***]% |   [***]% |
| PAT-2700-CA1  | Method                  and Apparatus for Preparation of Lipid Vesicles           | Canadian                  Patent Application No. 2,378,430 PENDING                                                                               | Knopov,                  V.Dzubanov,                  K. Harper, K. Cullis,                  P. |   UBC       |   INEX |   [***]% |   [***]% |   [***]% |
| PAT-2700-EP1  | Method                  and Apparatus for Preparation of Lipid Vesicles           | European                  Patent Application No. 00949025.1 PENDING                                                                              | Knopov,                  V.Dzubanov,                  K. Harper, K. Cullis,                  P. |   UBC       |   INEX |   [***]% |   [***]% |   [***]% |

----

|   **Inex                    File Number** |   **Title** |   **Serial/                    Patent Numbers** |   **Inventors** |   **Origin** |   **Ownership                    of Prosecution** |   **Hana                    Cost Allocation** |   **UBC                    Royalty** |  **UBC                    Sublicense                    Royalty** |
|-----------------------------------------------------|-----------------------|-----------------------------------------------------------|---------------------------|------------------------|-------------------------------------------------------------|---------------------------------------------------------|------------------------------------------------|------------------------------------------------------------------------|

| PAT-2700-JP1  | Method                  and Apparatus for Preparation of Lipid Vesicles           | Japanese                  Patent Application No. 2001-510430 PENDING | Knopov,                  V.Dzubanov,                  K. Harper, K. Cullis,                  P. |   UBC |   INEX |   [***]% |   [***]% |   [***]% |
|---------------|-----------------------------------------------------------------------------------|---------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|-----------------|------------------|--------------------|--------------------|--------------------|
| PAT-2700-US1  | Method                  and Apparatus for Preparation of Lipid Vesicles           | U.S.                  Patent Application No. 10/019,200 PENDING      | Knopov,                  V.Dzubanov,                  K. Harper, K. Cullis,                  P. |   UBC |   INEX |   [***]% |   [***]% |   [***]% |
| PAT-2700-CNT1 | Methods                  for Preparation of Lipid-Encapsulated Therapeutic Agents | U.S.                  Patent Application No. 11/359,999  PENDING     | Maurer,                  N.Wong,                  K.Cullis,                  P.                 |   UBC |   INEX |   [***]% |   [***]% |   [***]% |

----

**Schedule        “B” to Sublicense Agreement**

**ROYALTIES**

**In        each case where:**

| **A** | = | Number                  of UBC credited inventors who have not signed waivers of interest                  in                  royalties received by UBC, and |
|-------|---|---------------------------------------------------------------------------------------------------------------------------------------------------------------|
| **B** | = | Total                  Number of UBC credited inventors.                                                                                                      |

**Royalties        on Revenues Due UBC**

**A/B**

----

**Royalties        on Sublicensing Revenues Due UBC**

**A/B**

----